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Abstract 
 
Sucrase isomaltase (SI) and maltase glucoamylase (MGAM) are both large Family 31 
glycoside hydrolases with α-glucogenic activity (Cantarel et al., 2009; Lombard et al., 2014).  
Mammalian SI and MGAM, expressed predominantly in the small intestine, play essential roles 
in the process of starch digestion. Because their activities directly control the rate of α-
glucogenesis in the small intestine, they also pose a useful target for the design of α-glucosidase 
inhibitors, a class of drugs useful for the treatment of type 2 diabetes and other metabolic 
disorders. 
The purpose of this work was to characterize inhibition kinetics for enantiomeric 
pyrrolidine iminosugars 1,4-dideoxy-1,4-imino-L-arabinatol (LAB-1) and 1,4-dideoxy-1,4-
imino-D-arabinatol (DAB-1) with N- and C-terminal catalytic subunits of SI and MGAM, as 
well as for an additional C-terminal MGAM isoform, in the presence of three different 
substrates.  Kinetic analysis indicates that LAB-1 is a more potent inhibitor of maltose and PNP-
glucose hydrolysis than is DAB-1.  Both mixed and competitive inhibition kinetics are observed 
for varying combinations of inhibitor, enzyme, and substrate.  A general hypothesis regarding the 
binding of each of the two inhibitors is presented.  Additionally, evidence for substrate inhibition 
of palatinose hydrolysis for Nt-SI and Nt-MGAM is reported and discussed. 
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Chapter 1 Introduction 
 
1.1 Physiology and pathology of mammalian maltase glucoamylase 
and sucrase isomaltase 
 
Starch digestion in mammals is mediated by a consortium of enzymes which work 
together to provide a series of hydrolytic activities to ultimately liberate glucose for cellular 
metabolism (Quezada-Calvillo et al., 2007).  To initiate this process, salivary and pancreatic α-
amylases hydrolyze the internal α-1,4 glycosidic bonds of starch (Auricchio et al., 1965; 
Truscheit et al., 1981).  A mixture of shorter branched oligomers (α-limit dextrins), linear 
maltooligosaccharides and maltose are liberated and become substrates for the small intestinal 
brush border α-glucosidases sucrase isomaltase (SI) and maltase glucoamylase (MGAM) 
(Auricchio et al., 1965; Truscheit et al., 1981).  These enzymes are anchored by their N-termini 
to enterocytes in the mammalian small intestine (Nichols et al., 2003).  
SI and MGAM, two large paralogous glycoproteins (Nichols et al., 2003; Naumoff, 
2007), provide a spectrum of redundant and contrasting activities against the oligomeric products 
of starch digestion by α-amylases (Nichols et al., 2009).  Both human enzymes are composed of 
two catalytic subunits, the N- and C-termini (Quezada-Calvillo et al., 2009).  All four subunits 
exhibit catalytic activities, and all are classified as Family 31 glycoside hydrolases, based on 
similarity of amino acid sequences (Cantarel et al., 2009; Lombard et al., 2014).  Characterized 
by their general ability to transfer the glycosyl group from a substrate to water, glycoside 
hydrolases may hydrolyze substrates though either a retaining (double displacement) or an 
inverting (single displacement) mechanism (Koshland, 1953; Sinnott, 2007).   Family 31 is 
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comprised of retaining glycoside hydrolases, for which products of hydrolysis have the same α or 
β configuration as the substrate (Lombard et al., 2013).  
 
 
Figure 1.  Retaining mechanism for glycoside hydrolases. 
k 
The retaining mechanism, proposed by Dan Koshland in 1953 (Koshland, 1953), proceeds through 
general acid catalysis and requires both a proton donor and a nucleophilic base (Davies and Henrissat, 
1995).  This double displacement mechanism involves the formation and hydrolysis of a covalent 
glycosyl-enzyme intermediate (McCarter and Withers, 1994).  Two transition state species are formed, 
each a result of a separate displacement reaction (Rye and Withers, 2000). 
 
Apparent redundancies in activities between catalytic subunits are thought to have 
evolved to allow for the improved digestion of many different types of starches from various 
botanical origins (Nichols et al., 2009). 
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1.1.1 Physiological roles 
 
 
Each of the SI and MGAM catalytic subunits has a characteristic set of substrate 
specificities (Jones et al., 2011; Lee et al., 2014).  It is still not fully understood how these 
enzymes work together to perform the combination of hydrolytic functions required for the 
effective digestion of different complex carbohydrates (Lee et al., 2014).  Hydrolysis kinetics for 
a variety of substrates have, however, been well-characterized (Gray et al., 1979; Jones et al., 
2011; Lee et al., 2014; Auricchio et al., 1965).   Albeit with differing efficiencies, all four of the 
subunits are able to hydrolyze the α-1,4 glycosidic linkage of maltose (Gray et al., 1979; Jones et 
al., 2011).  Differences in substrate specificities provide important information about the 
individual roles played by each of these enzymes: the C-terminal subunit of SI, for instance, is 
unique in its ability to hydrolyze the α-1,2 linkage of sucrose, while the N-terminal subunit is 
capable of effectively hydrolysing the α-1,6 linkage of isomaltose (Gray et al., 1979; Sim et al., 
2010).  The N-terminal subunit of MGAM exhibits some isomaltase activity, but it is much less 
effective than the activity provided by Nt-SI (Lee et al., 2014).  Ct-MGAM has demonstrated no 
isomaltase activity at all (Lee et al., 2014).  It is thought that the general role of MGAM in the 
small intestine is to digest linear regions of oligomeric starch breakdown products, while sucrase 
isomaltase is responsible for the hydrolysis of branched linkages (Naumoff, 2007).  The 
biological advantage of this spectrum of different hydrolytic activities is that it provides an 
organism with the capacity to derive glucose from a vast array of different complex 
carbohydrates (Lee et al., 2014). 
In addition to two catalytic subunits, both SI and MGAM also possess a transmembrane 
domain and an O-glycosylated stalk or “linker” region (Naumoff, 2007).  The N-termini of SI 
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and MGAM are both located on the inside of the enterocyte membrane, while C-termini extend 
out into the small intestinal lumen (Semenza, 1986; Naim et al., 1988).  Catalytic subunits all 
extend into the intestinal lumen.  An SI precursor protein known as Pro-SI is cleaved in vivo by 
pancreatic proteases to yield separate component subunits sucrase and isomaltase (Semenza, 
1986; Naim et al., 1988).  After cleavage, these two catalytic subunits remain in close proximity 
to one another (Semenza, 1986).  While potential effects of this interaction on catalytic functions 
of the subunits remain unclear, discrete subunits have displayed catalytic activities in vitro (Lee 
et al., 2014).  In contrast, maltase glucoamylase does not undergo proteolytic processing, and N-
and C-terminal subunits are covalently linked (Naim et al., 1988). 
The gene for human sucrase isomaltase is encoded on chromosome 3q25-26 (West et al., 
1988), and the gene for human maltase-glucoamylase is encoded on chromosome 7q34 (Nichols 
et al., 2003).  Both SI and MGAM are considered to be the product of two ancestral duplication 
events (Naumoff, 2007; Nichols et al., 2003).  In most mammals, the C-terminal coding 
sequence of MGAM is composed of a series of internal tandem duplications, and different 
mammals exhibit different numbers of duplications (Sim, 2010).  Alternative splicing of this 
region results in the expression of several different Ct-MGAM spliceforms, each containing 
different parts of the variable region (Sim, 2010).  Each spliceform of Ct-MGAM possesses the 
glycoside hydrolase Family 31 amino acid signature sequence WIDMNE, although in different 
spliceforms, this sequence is located in different positions (Sim, 2010). 
The spliceforms used in the present work are Ct-MGAM N2 and N20, both from mice 
(Sim, 2010).  Interestingly, these two proteins exhibit some discrepancies in substrate specificity; 
for instance, Ct-MGAM N2 has been observed to have a four-fold higher affinity for maltose as 
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a substrate than Ct-MGAM N20 (Sim, 2010).  Whether or not there are comparative differences 
in inhibitor potency with respect to these two spliceforms is a question of special interest. 
In the present study, recombinant N-terminal subunits of SI and MGAM are human 
enzymes, while C-terminal subunits, Ct-SI, Ct-MGAM N2, and Ct-MGAM N20, are mouse 
enzymes (Sim, 2010).  The amino acid sequence similarity of mouse Ct-SI and human Ct-SI is 
78%, and the overall amino acid sequence similarity of mouse MGAM and human MGAM is 
greater than 80% (Sim, 2010).  It is still fair to suppose that inferences made about human C-
terminal enzymes from results observed for mouse C-terminal enzymes will be limited in scope.  
Although the overall architectures of these enzymes are similar, differences in amino acids 
present around the active site may cause the human and mouse enzymes to have quite different 
substrate specificities (Sim, 2010). 
 
1.1.2 Pathology 
 
 
The digestion of complex carbohydrates, including many different botanical varieties of 
starch, is an essential function in mammals (Quezada-Calvillo et al., 2007).  Unfortunately, 
normal digestive functions can be thwarted by a variety of genetic irregularities, including the 
mutation of a gene encoding an enzyme essential to this process (Jacob et al., 2002).  Congenital 
sucrase isomaltase disorder (CSID) is an example of a disease with complicated and devastating 
effects, caused directly by mutations to the gene encoding SI, which plays a critical role in starch 
metabolism (Jacob et al., 2002).  Pathology can also develop over time in the presence of 
physiological abnormalities; for instance, diabetes mellitus type 2 and other metabolic disorders 
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involve pathological changes to the normal physiological system which disrupt regular 
metabolism and can lead to long-term complications and ill health (Florez, 2008). 
Like many metabolic disorders, type 2 diabetes is the product of both genetic and 
environmental factors (Florez, 2008).  It has historically been characterized as an insulin-
resistant state, but it remains unclear whether the associated disease state results primarily from 
insulin resistance or from insufficient insulin secretion (Florez, 2008; Lillioja et al., 1993; 
Gerich, 2000).  Many long-term complications associated with type 2 diabetes are caused by 
hyperglycaemia, or elevated levels of plasma glucose in blood, over a long period of time 
(Gerich, 2000). 
The disease state is highly correlated with obesity, and lifestyle factors such as diet and 
exercise are very important in its treatment (Gerich, 2000).  Many classes of oral antidiabetic 
agents are also available for the treatment of type 2 diabetes, if nonpharmacological measures 
prove insufficient (Krentz and Bailey, 2005).  Among the popular oral agents are sulphonylureas, 
a class of compounds which stimulate insulin secretion; biguanides, which cause decreased 
gluconeogenesis and reduced plasma glucose; thiazolidinediones, which activate a particular 
group of nuclear receptors and cause enhanced insulin sensitivity; and α-glucosidase inhibitors, 
which help to control the rate of digestion of carbohydrates in the small intestine (Krentz and 
Bailey, 2005).  Proper glycaemic control is a main treatment target for this disease, and several 
classes of oral agents address it directly. 
The α-glucosidase inhibitor acarbose, introduced onto the market in the 1990s, was the 
first of its class to become available for the treatment of type 2 diabetes (Krentz and Bailey, 
2005).  Compounds of this class bind with high affinity to α-amylases, sucrase isomaltase, 
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maltase glucoamylase, or a combination of these enzymes, thereby inhibiting the hydrolysis of 
starch, oligosaccharide and disaccharide substrates (Krentz and Bailey, 2005).  This reduces the 
amount of monomeric glucose available for absorption along the intestinal tract (Krentz and 
Bailey, 2005).  Larger oligomers, which would normally be hydrolyzed early on, travel further 
along the intestinal tract,  ultimately causing the delayed absorption of glucose and 
circumventing the incidence of “spikes” in blood glucose, also known as postprandial 
hyperglycaemia (Krentz and Bailey, 2005; van de Laar et al., 2005).  The most common adverse 
effects associated with antidiabetic agents of this class are gastrointestinal in nature, due to the 
passage of undigested oligomeric carbohydrates into the large intestine, where they become 
substrates for the microflora of that environment (Krentz and Bailey, 2005).  This can result in 
abdominal discomfort, flatulence, and diarrhoea (Krentz and Bailey, 2005). 
α-glucosidase inhibitors are an attractive class of oral antidiabetic agents because they are 
generally associated with low levels of toxicity and they do not cause weight gain (van de Laar et 
al., 2005).  Since the 1990s, several new α-glucosidase inhibitors have been introduced, 
including miglitol and voglibose (Krentz and Bailey, 2005).  Salacia reticulata extract, 
containing inhibitors of the thiosugar sulfonium sulfate class, has also been shown in one double-
blind study to be an effective treatment for human patients with type 2 diabetes, with few 
deleterious effects (Jayawardena et al., 2005). 
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1.2 Elementary enzyme kinetics and inhibition kinetics 
The first recorded observations of cell-free activity for biological samples date back to 
the late 1700s (Segel, 1975).  Throughout the 1800s, a new idea emerged; this was the idea that 
cell-free activity, affecting the change of one substance into another, must be attributable to the 
presence of a kind of chemical catalyst (Segel, 1975).  Today these chemical catalysts are known 
as enzymes, with almost innumerable functional roles in biological systems.  Enzymes serve to 
decrease the activation energy required for a chemical reaction by providing an alternative 
mechanism to transform one or more substrates into products (Segel, 1975). 
 
1.2.1 Unireactant steady-state kinetics for enzyme-catalyzed reactions 
 For the very simple case of an enzyme-catalyzed reaction with a single substrate, a single 
enzyme, and a single intermediate enzyme-substrate (ES) complex, the following scheme 
describes the reaction progress and indicates rate constants (Cornish-Bowden, 1997; Copeland, 
2000).  First the enzyme binds the substrate; the strength of this interaction is proportional to the 
magnitude of k1, the rate constant for the formation of ES (Copeland, 2000; Stein, 2011).  
Dissociation of ES back to E and S is governed by the reverse rate constant, k-1 (Copeland, 
2000).  k2 is, in the simplest case, the catalytic rate constant, and k-2 is the rate constant of the 
reverse reaction (often of negligible magnitude) (Copeland, 2000). 
 
Figure 2.  General scheme for an enzyme-catalyzed reaction. 
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The rate constant k2, describing only a simple scenario where no additional complexes 
are formed subsequent to formation of the ES complex, is often insufficient to describe more 
complex reaction mechanisms.  For instance, several intermediate complexes may be formed 
before products are released (Segel, 1975).  It is therefore necessary to describe most enzyme-
catalyzed reactions using kcat, a constant which governs the rate-limiting or slowest step in a 
series of post-ES catalytic reactions (Copeland, 2000). 
In 1903, Victor Henri proposed the idea that enzyme-catalyzed reactions involved the 
formation of an enzyme-substrate complex at some point along the reaction coordinate (Henri, 
1903).  He independently derived a mathematical equation, later rediscovered and modified by 
the German biochemist Leonor Michaelis and by the Canadian physician Maud Menten, to 
describe the change in reaction velocity as a function of substrate concentration (Segel, 1975). 
𝑣
𝑉𝑚𝑎𝑥
=  
[𝑆]
𝐾𝑠 + [𝑆]
 
Equation 1.  Henri-Michaelis-Menten equation for slow reaction kinetics (Segel, 1975). 
where v = initial velocity (instantaneous reaction velocity, d[P]/dt or d[S]/dt) 
 Vmax = maximal reaction velocity; observed when all E present has been converted to ES 
 [S] = substrate concentration 
 Ks = k-1/k1 =  the dissociation constant for the ES complex   ≈  Km  when k2<<k-1 
 
 When the magnitude of rate constant k2 is not negligible – that is, when slow reaction 
kinetics are not observed, the equation becomes 
𝑣
𝑉𝑚𝑎𝑥
=  
[𝑆]
𝐾𝑚 + [𝑆]
 
Equation 2.  General Henri-Michaelis-Menten equation (Copeland, 2000). 
where Km = (k2 + k-1)/k1 
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Km, the Michaelis constant, is distinctive for each given enzyme reacted with a given 
substrate (Segel, 1975).  It is defined as the substrate concentration required for the instantaneous 
reaction velocity to reach half the magnitude of the maximal reaction velocity (Copeland, 2000).  
More complex kinetics, including those describing the activities of enzymes that do not follow 
rapid equilibrium kinetics, as well as for multireactant systems, were characterized later on in the 
twentieth century (Segel, 1975). 
In 1913, the “steady state” concept was first described by Max Bodenstein, a German 
physical chemist, and was later found to be applicable to enzyme kinetics by George Briggs and 
J. B. S. Haldane (Segel, 1975; Stein, 2011).  The essence of the steady state assumption is that 
any intermediate in a multistep reaction exists at a constant concentration; the rate of formation 
and the rate of decay are equivalent in magnitude (Stein, 2011).  For a unireactant system with a 
single ES complex, this means that [ES] is not changing over the course of the reaction time. 
Requirements of the steady state condition are listed as follows (Copeland, 2000): 
 [S]>>[E] 
The substrate concentration must be significantly greater than the total enzyme concentration.  The 
amount of unbound substrate is not appreciably depleted by formation of the ES complex. 
 [E]t = [E]+ [ES]  
 The total quantity of enzyme present does not change over the course of the reaction. 
  [P]o = 0 
There are no products present at the initiation of the reaction. 
 
Catalytic subunits of SI and MGAM, the enzymes relevant to the present work, are 
considered here as part of a unireactant system at steady state. 
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1.2.2 Linear inhibition kinetics for reversible inhibitors 
 
Iminosugars, including LAB-1 and DAB-1, are reversible inhibitors of glycoside 
hydrolases (Stϋtz, 1999; Butters et al., 2005).  In general, reversible inhibition can be subdivided 
into two categories: linear inhibition and nonlinear inhibition (Segel, 1975).  Linear inhibition 
involves the formation of one or more nonproductive complexes resulting from a binding 
interaction between an inhibitor and an enzyme, or between an inhibitor and an enzyme-ligand 
complex (Leskovac, 2003).  This type of inhibition can be further classified as competitive, 
noncompetitive (a form of mixed inhibition), or uncompetitive (Leskovac, 2003). 
 
Figure 3.  General scheme for linear inhibition of an enzyme-catalyzed reaction. 
`where Ki represents the dissociation constant for the EI complex 
Ki’ represents the dissociation constant for the EIS complex 
 α represents the constant relating Ki and Ki’ 
 
Competitive inhibition occurs when an inhibitor binds to an enzyme’s active site, thereby 
precluding binding of the substrate (Leskovac, 2003).  The concentration of products is directly 
dependent on the concentration of a competitive inhibitor in solution (Segel, 1975).  Henri-
Michaelis-Menten kinetics are altered by the presence of a competitive inhibitor in a predictable 
way; the Michaelis constant, Km, is increased (Leskovac, 2003).  This is because binding of an 
inhibitor to the free enzyme causes a shift in chemical equilibrium which favours dissociation of 
the ES complex as a result of Le Châtelier’s principle (Clugston and Fleming, 2000).  Equation 3 
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describes the relationship between Km and the apparent Km (Km
app) in the presence of a 
competitive inhibitor. 
𝐾𝑚
𝑎𝑝𝑝 =  𝐾𝑚(1 +
[𝐼]
𝐾 𝑖
) 
Equation 3.  Relationship between apparent Km and actual Km in the presence of a 
competitive inhibitor (Segel, 1975). 
 
 
Noncompetitive inhibition refers to a type of inhibition observed when an inhibitor binds 
with equal preference both to the free enzyme and to the ES complex (Segel, 1975).  The extent 
of dissociation of the two complexes formed, namely EI and EIS, is described by the magnitudes 
of constants Ki and Ki’, respectively.  In this scenario, the inhibitor binding site is independent of 
the substrate binding site, and Ki and Ki’ are equal in magnitude (Segel, 1975).  
𝑉𝑚𝑎𝑥
𝑎𝑝𝑝 =  
𝑉𝑚𝑎𝑥
(1 +  
[𝐼]
𝐾𝑖′
)
 
Equation 4.  Relationship between apparent Vmax and actual Vmax in the presence of a 
mixed, noncompetitive, or uncompetitive inhibitor (Segel, 1975). 
Vmax
app represents the observed maximal reaction velocity 
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Uncompetitive inhibitors bind only to the ES complex, affecting a decrease in the 
parameter Km due to a shift in chemical equilibrium which must favour the formation of the ES 
complex (Clugston, 2000).  Equation 5 illustrates the relationship between actual Km and 
apparent Km in the presence of an uncompetitive inhibitor. 
Binding of an uncompetitive inhibitor also reduces the rate of catalysis, causing an 
equivalent decrease in Vmax which can be described by Equation 4.  Because some enzyme will 
always be present in the inactive ESI form, in this scenario, it is not possible to drive all of the 
enzyme present into the ES form, even with an infinitely high concentration of substrate (Segel, 
1975). 
𝐾𝑚
𝑎𝑝𝑝 =  
𝐾𝑚
(1 + 
[𝐼]
𝐾𝑖′
)
 
Equation 5.  Relationship between apparent Km and actual Km in the presence of an 
uncompetitive inhibitor (Segel, 1975).  
 
 
A mixed inhibitor will bind both to E and to the ES complex, with a higher affinity for 
one form than for the other, causing Ki and Ki’ to be of different magnitudes (Segel, 1975).
  Both 
the Michaelis constant and the maximal reaction velocity will be affected by the binding of this 
class of inhibitor; the extents to which they are affected will differ, however.  The change in Km 
observed as a result of the binding of a mixed inhibitor is illustrated in Equation 6.  As can be 
seen from Equation 4, the apparent Vmax is decreased in the presence of this type of inhibitor. 
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𝐾𝑚
𝑎𝑝𝑝 =  𝐾𝑚
(1 +
[𝐼]
𝐾𝑖
) 
(1 +  
[𝐼]
𝐾𝑖′
)
 
Equation 6.  Relationship between apparent Km and actual Km in the presence of a mixed 
inhibitor (Segel, 1975). 
 
 Linear mixed inhibition can result from several different situations.  It may be the result 
of an inhibitor binding to a single site and altering the affinity the enzyme has for its substrate, as 
well as the enzyme’s ability to effectively catalyze the reaction (Segel, 1975).  This type of 
inhibition may also result when an inhibitor binds at two distinct sites on the enzyme (Segel, 
1975).  In the latter case, binding of one inhibitor molecule must obstruct binding of the 
substrate, and while binding at the second site has no effect on substrate binding, it does produce 
a catalytically inactive ESI complex (Segel, 1975).  In some cases, IEI complexes can form if 
inhibitor binding events at two sites are not mutually exclusive (Segel, 1975). 
1.2.3 Nonlinear inhibition kinetics for reversible inhibitors 
 
 Nonlinear inhibition kinetics in monosubstrate reactions may result from several different 
phenomena (Leskovac, 2003).  One case of nonlinear inhibition kinetics is when a productive 
ESI complex forms (Segel, 1975; Whitely, 1997).  This phenomenon is governed by hyperbolic 
inhibition kinetics, named for the character of the secondary replots which distinguish them from 
linear or parabolic inhibition kinetics (Leskovac, 2003).  When the ESI complex can yield 
products with no loss of catalytic activity, the system demonstrates hyperbolic competitive 
inhibition kinetics (Segel, 1975).  Hyperbolic mixed inhibition is also possible: in this case, both 
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the ES complex and the ESI complex can yield products, but the ESI complex has decreased 
catalytic activity and therefore cannot render products as effectively (Segel, 1975).  Hyperbolic 
noncompetitive and hyperbolic uncompetitive inhibition systems are similar to their linear 
counterparts, with the sole difference being development of products from an ESI complex 
(Leskovac, 2003).  Indeed, all instances of hyperbolic inhibition are partial in nature, and a 
saturating concentration of inhibitor cannot completely quench the reaction; some enzyme will 
always be present in the EIS form, rendering products (Leskovac, 2003). 
 Nonlinear inhibition kinetics may also be the result of multiple inhibitor binding events – 
this is referred to as parabolic inhibition (Leskovac, 2003).  Parabolic inhibition is considered a 
type of complete inhibition, because under conditions of saturating [I], all enzyme present will be 
driven to an inactive form, IEI (Leskovac, 2003). 
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1.3 A review of iminosugar inhibitors and thiosugar sulfonium salts 
 
 In the discovery and development of candidate inhibitors of mammalian α-glucosidases, 
iminosugars and thiosugar sulfonium salts have been among the most rigorously researched 
classes of compounds (de Melo et al., 2006).  The isolation of naturally-occurring compounds 
such as nojirimycin, from Streptomyces sp. (Ishida et al., 1967), and salacinol, from Salacia 
reticulata (Yoshikawa et al., 1997), instigated a hunt for similar natural compounds and 
informed the rational design of biologically-active derivatives.  The following sections will 
provide a review of the structural differences and biological activities of piperidine and 
pyrrolidine iminosugar inhibitors.  Structural differences and biological activities of thiosugar 
sulfonium sulfates will be reviewed thereafter. 
1.3.1 Piperidine and pyrrolidine iminosugars 
 
Both naturally-occurring and synthetically-derived iminosugars have been well-
characterized as inhibitors of an impressive variety of enzymes, including but not limited to α- and 
β-glucosidases, glycosyl transferases, phosphorylases, sugar-nucleotide mutases, and glycogen 
phosphorylases (Rule et al., 1985; Fleet et al., 1985; Evans et al., 1985; Scofield et al., 1986; de 
Melo et al., 2006; Andersen et al., 1999).  Inhibitors of this class have been most actively studied 
for their often potent effects on α-glucogenic activities (Asano, 2003).  For this reason, iminosugar 
inhibitors have long been of interest as potential antidiabetic agents. 
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1.3.1.1 Iminosugars: Structural Characteristics and Mechanisms of Inhibition 
 
Iminosugars are generally classified by the nature of the ring structures of which they are 
composed.  Monocyclic iminosugars include pyrrolidines, which resemble furanose rings, and 
piperidines, which resemble pyranose rings (Asano et al., 2005).  Many bicyclic alkaloid 
structures, including indolizidines, pyrrolizidines, and nortropanes, have also been identified as 
glycosidase inhibitors (de Melo et al., 2006; Asano et al., 2000; Molyneux et al., 2002). 
The piperidine iminosugar nojirimycin (NJ), originally isolated in 1966 as an antibiotic 
from Streptomyces roseochromogenes (Ishida et al., 1967), has been identified as an inhibitor of 
both α- and β-glucosidic activities (de Melo et al., 2006; Asano et al., 2000).  Like other piperidine 
iminosugars, NJ is a six-membered heterocyclic compound containing endocyclic nitrogen (Asano 
et al., 2000).  Well-studied NJ derivatives include 1-deoxynojirimycin (DNJ) and 
deoxygalactonojirimycin (DGJ) (Asano et al., 2000).         
 
          
 
Figure 4.  Basic chemical structures of four classes of iminosugar inhibitors:  1, 
pyrrolidines, 2, piperidines, 3, indolizidines, and 4, pyrrolizidines. 
 
 
 
Pyrrolidine and piperidine iminosugars, including NJ, have frequently been described as 
substrate mimics, and ostensibly influence substrate binding by means of competition for an 
enzyme's active site (de Melo et al., 2006; Asano et al., 2000).  There exist several hypotheses 
1 2 3 4 
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about the general mechanism by which iminosugars exert inhibitory effects, but they are all 
based on the fundamental concept of structural mimicry (de Melo et al., 2006; Asano et al., 
2005).  Many iminosugars are highly effective inhibitors of glycosidases, and it is widely 
accepted that this is generally because they structurally mimic either a unit of a natural substrate 
or a transition state species (de Melo et al., 2006; Asano et al., 2005). 
The transition state species in a glycosidic cleavage reaction is considered the molecular 
structure with the highest potential energy along the reaction coordinate (Nash et al., 1965; 
Ozaki et al., 2008).  This species requires enzymatic stabilisation in order for the reaction to 
proceed toward products (Nash et al., 1965).  Enzymes are evolved to very effectively stabilise 
transition state species so that they can perform highly specific functions (Nash et al., 1965).  For 
this reason, enzymes generally have very high affinities for molecules which are structurally 
similar to the transition state species of a natural biological reaction. 
1.3.1.2 Iminosugars: Biological Activities 
 
The inhibitory capacity of a pyrrolidine iminosugar of special interest, 1,4-dideoxy-1,4-
imino-D-arabinatol (DAB-1), was first characterized in 1985 by George Fleet and Paul Smith at 
Oxford University (Fleet et al., 1985).  Here, DAB-1 was identified as a competitive inhibitor of 
α-glucosidic activity from Brewer's yeast (Fleet et al., 1985).  Fleet and Smith also showed that 
DAB-1 was identical to a naturally-occurring compound previously isolated from Arachniodes 
standishii (Furukawa, 1985) and Angylocalyx boutiqueanus (Fleet et al., 1985; Nash et al., 1985).  
At this time, Fleet and Smith reported that the L-enantiomer, LAB-1, was a significantly weaker 
inhibitor of α-glucosidic activity from Brewer’s yeast (Fleet et al., 1985). 
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Figure 5.  Chemical structures of iminosugar inhibitors 5, DAB-1, 6, LAB-1, and 7, DNJ. 
 
In 1986, George Fleet and colleagues assayed the enantiomers LAB-1 and DAB-1 for 
inhibition of maltase and isomaltase activities of a mouse intestinal mucosal suspension (Scofield 
et al., 1986).  This series of experiments yielded an interesting result: in contrast to the relative 
inhibitory effects of LAB-1 and DAB-1 observed when tested with Brewer’s yeast α-glucosidase, 
against mammalian α-D-glucosidase activity, LAB-1 was found to have a potency of an order of 
magnitude greater than DAB-1 (Scofield et al., 1986).  It was concluded that the synthetic 
iminosugar LAB-1 was a more potent inhibitor of mammalian intestinal disaccharidase activity 
than was its D-enantiomer (Scofield et al., 1986).  Because purified recombinant mammalian 
intestinal α-glucosidases were unavailable at the time, it was not a practical possibility in 1986 to 
determine precise modes of inhibition associated with DAB-1 and LAB-1 (Scofield et al., 1986).   
Nonetheless, the relative potencies of these L-and D-enantiomers of pyrrolidine iminosugars, with 
respect to mammalian α-glucosidase activity, demonstrated the relevance of their structural 
differences and suggested the potential for heterogeneity in the compounds’ modes of inhibition 
(Scofield et al., 1986).  It has long been a subject in need of clarification. 
Since the early pioneering works of George Fleet and colleagues, differential inhibition by 
L- and D-enantiomers of polyhydroxy iminosugars has remained a subject of academic interest.  
In 2005, three pairs of iminosugar enantiomers were assayed for inhibition of a considerable 
5 6 7 
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number of enzymes, including α- and β-D-glucosidases, α- and β-D-mannosidases, α- and β-D-
galactosidases, and amyloglucosidase, from a number of different organisms (Asano et al., 2005).  
Iminosugars tested included LAB-1 and DAB-1, L- and D- isofagomine (piperidine iminosugars), 
and L- and D-DMDP (2,5-dideoxy-2,5-imino-mannitol; pyrrolidine imminosugars) (Asano et al., 
2005).  This investigation showed that the three D-enantiomers inhibited both yeast and rat α-D-
glucosidase activity in a purely competitive manner, while L-enantiomers exhibited purely non-
competitive inhibition against the same enzymes (Asano et al., 2005).  These results provoked the 
question of whether LAB-1 and DAB-1 were binding to the same site, or whether LAB-1 bound 
to a remote allosteric site (Asano et al., 2005).  The matter has not been definitively settled.   
A recent study investigated the inhibition of rat α-D-glucosidic activities by N-benzyl 
derivatives of pyrrolidine iminosugars (Carreiro et al., 2014).  Analysis of inhibition kinetics for 
N-benzylated compounds revealed several instances of weak mixed inhibition (Carreiro et al., 
2014).  Since iminosugar inhibitors commonly exhibit competitive inhibition kinetics (Krasikov et 
al., 2001), structural modifications that influence an inhibitor’s effects on substrate affinity and 
enzymatic catalysis may provide useful information for rational drug design. 
A central weakness of iminosugar inhibitors as a group is that many compounds are 
somewhat nonselective and exert diverse biological effects by interacting with an assortment of 
enzymes (Asano et al., 2005).  Interestingly, several iminosugars including LAB-1, 
castanospermine, and a host of DNJ derivatives, have demonstrated anti-HIV activities in vitro 
(Fleet et al., 1988; Greimel et al., 2003), and castanospermine specifically has been implicated in 
the blockage of mouse tumour cell metastasis via inhibition of glucosidase I, an enzyme which 
initiates the processing of N-linked glycoproteins (Humphries et al., 1986).  The fact that 
iminosugars demonstrate such a great variety of interactions makes them attractive as first-
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generation compounds for drug development while simultaneously decreasing their direct use in 
the treatment of metabolic disorders and disease (Horne et al., 2011). 
1.3.2             Thiosugar sulfonium sulfates 
 
Investigation of thiosugar sulfonium sulfates began in 1990, when a research group from 
Toyama, Japan characterized the effects of an aqueous Salacia reticulata extract on plasma 
glucose levels in streptozotocin-induced diabetic rats (Serasinghe et al., 1990).  Salacia 
reticulata has been used traditionally in the Ayurvedic system of Indian Medicine to treat 
diabetes (Yoshikawa et al., 1997).  Biochemical investigations of oral hypoglycaemic activity of 
aqueous extracts from S. reticulata root bark were first reported in 1997, when Masayuki 
Yoshikawa et al. described the thiosugar sulfonium sulfate structure of the antidiabetic agent 
salacinol (Yoshikawa et al., 1997).  This initiated a wave of investigations into the effects of 
other thiosugar sulfonium sulfates present in S. reticulata extracts, as well as synthetically-
produced derivatives. 
As a result, another yet more potent antidiabetic principle was isolated from aqueous S. 
reticulata extract; this compound, called kotalanol, differed from salacinol only by the nature of 
the side chain extending off of the ring sulfur atom (Yoshikawa et al., 1998).  The sulfate group 
present on the side chain of kotalanol is oriented slightly differently in space, and the side chain 
itself is seven carbon atoms in length, while the side chain of salacinol is only four carbon atoms 
in length (Yoshikawa et al., 1997; Yoshikawa et al., 1998).  The significance of stereochemistry 
of the hydroxyl groups located at different positions on the kotalanol side chain would not be 
demonstrated before nearly a decade had passed (Tanabe et al., 2012).  In the meantime, side 
chain analogues ponkoranol and salaprinol (Yoshikawa et al., 2008) and de-O-sulfonated 
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analogues (Minami et al., 2008; Ozaki et al., 2008; Muraoka et al., 2008)) were isolated and 
characterized in a series of different ventures. 
 
Figure 6.  Chemical structures of two compounds isolated from Salacia reticulata: salacinol 
(9) and kotalanol (9). 
 
1.3.2.1 Thiosugar sulfonium sulfates: Structural Characteristics and 
Mechanisms of Inhibition 
 
Structurally, thiosugar sulfonium salts bear some similarities to the pyrrolidine 
iminosugars relevant to the present investigation; the five-membered rings of salacinol and 
kotalanol resemble the furanose-like ring of DAB-1 with respect to hydroxyl group 
stereochemistry, but include sulfur as the ring heteroatom instead of nitrogen (Yoshikawa et al., 
1997; Yoshikawa et al., 1998; Yoshikawa et al., 2002).  Structural characteristics such as ring 
hydroxyl group stereochemistry (Mohan and Pinto, 2007), the nature of the ring heteroatom 
(Gallienne et al., 2006; Mohan and Pinto, 2007), side chain stereochemistry (Tanabe et al., 2012; 
Mohan and Pinto, 2007), variation of chiral centers (Gallienne et al., 2006), and variation of ring 
size (Gallienne et al., 2006) all play an important role in determining the potency of thiosugar 
sulfonium sulfates and related inhibitors.   
Thiosugar sulfonium sulfates have distinctive zwitterionic structures, relying on 
stablilization of the ring sulfonium cation by a sulfate anion provided by the side chain 
8 9 
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(Gallienne et al., 2006; Mohan and Pinto, 2007; Lillelund et al., 2007).  It is thought that 
salacinol exerts inhibitory effects by mimicking an oxocarbenium-ion-like transition state species 
in the hydrolysis of natural polysaccharide or glycoside substrates (Gallienne et al., 2006).  
There is great variability in potency associated with this class of inhibitors, with respect to 
different glycosidases of different origins (Yuasa et al., 2001).  For these inhibitors, it is 
purported that potency with respect to different enzymes is directly related to how accurately the 
structure of the inhibitor mimics the structure of an oxocarbenium-ion-like transition state (Stϋtz, 
1999).  As is the case with the iminosugar inhibitors, the ring heteroatom of this class of 
inhibitors is thought to provide a positive charge to mimic the partial positive charge on the 
endocyclic oxygen atom of a transition state (Stϋtz, 1999).  
There is ample evidence that electrostatic interactions also play an important role in the 
determination of the potencies of different thiosugar sulfonium sulfate inhibitors (Stϋtz, 1999; 
Ghavami et al., 2001).  Structural modifications which exploit hydrogen bonding phenomena via 
altered hydroxyl group stereochemistry, or which exploit electrostatic and hydrophobic 
interactions, are therefore key to the development of successful inhibitors.    
1.3.2.2 Thiosugar sulfonium sulfates: Biological Activities 
 
Naturally-occurring compounds isolated from S. reticulata (Yoshikawa et al,, 1997; 
Yoshikawa et al., 1998; Ozaki et al., 2008) and related species including S. prinoides 
(Yoshikawa et al., 2008) are thought to be a by-product of coevolution between plants and the 
herbivores and omnivores that consume them (Marles and Farnsworth, 1995).  These 
hypoglycaemic agents are generally considered chemical defense compounds evolved by plants 
to deter predators (Marles and Farnsworth, 1995).  Since it is advantageous for plants to produce 
24 
 
chemicals which can affect a broad range of predators, active compounds isolated from a natural 
source often exhibit poor selectivity (Marles and Farnsworth, 1995).  This may explain why 
structures of naturally-occurring iminosugars and thiosugar sulfonium sulfates are such that they 
inhibit the functions of a variety of different enzymes. 
Salacinol analogues have shown inhibitory activities against mammalian α-glucosidases 
(Jones et al., 2011) and against a Drosophila homologue of human Golgi α-mannosidase II 
(Kuntz et al., 2005),  and certain derivatives have demonstrated activities against β-glucosidases 
(Gallienne et al., 2005) and β-galactosidases (Gallienne et al., 2006).  Several analogues exhibit 
the capacity to bind to more than one target enzyme (Jones et al., 2011; Kuntz et al., 2005).  If a 
compound is intended as a candidate drug for the treatment of a metabolic disorder, it is essential 
that the compound does not interact non-selectively with a broad range of enzymes present in the 
human body.  In order to improve the selectivity of these compounds, it is necessary to examine 
the precise effects that controlled structural modifications have on inhibition kinetics. Even 
apparently minor changes to an inhibitor’s structure can dramatically alter its selectivity 
(Gallienne et al., 2006). 
Salacinol and kotalanol exhibit classic competitive inhibition kinetics with recombinant 
subunits of both human maltase glucoamylase and sucrase isomaltase (Rossi et al., 2006; Sim, 
2010; Sim et al., 2010; Jones et al., 2011).  For maltose hydrolysis reactions in the presence of 
salacinol and kotalanol, inhibition constants are all in the low micromolar or nanomolar range 
(Jones et al., 2011).  The incidence of differential competitive inhibition of recombinant SI and 
MGAM subunits reinforces the notion that the active site architectures for each of these enzymes 
have evolved to perform a characteristic set of functions.  The competitive inhibition associated 
with this class of compounds indicates that they bind in the active site of affected enzymes, 
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thereby impeding substrate binding (Sim et al., 2010).  In 2008, a crystal structure of Nt-MGAM 
was reported in complex with acarbose (Sim et al,, 2008), and in 2010, the same group obtained 
the crystal structure of Nt-SI in complex with kotalanol (Sim et al., 2010).  Both inhibitors were 
found in the active sites of the respective structure (Sim et al., 2010).  These reports laid the 
groundwork for the development of inhibitors that might be tailored to the unique active site 
features of the different mammalian small intestinal α-glucosidases. 
 
1.4 Thesis Objectives 
The value of characterizing inhibition kinetics for compounds with inhibitory activities 
against mammalian digestive α-glucosidases is twofold.  Firstly, such research can elucidate the 
various mechanisms by which inhibitors and enzymes interact; it can also serve to clarify how or 
if the structures of different substrates affect this relationship.  Secondly, it may provide 
information about structural characteristics of enzyme active sites – information that may prove 
invaluable in the hunt for potent and highly selective α-glucosidase inhibitors. 
The second chapter of this thesis will describe assays performed for the purpose of 
characterizing inhibition kinetics of LAB-1 and DAB-1 with five different intestinal α-
glucosidases and the disaccharide maltose, which is composed of glucose units connected by an 
α-1,4 glycosidic linkage.  Chapter 2 will also outline the execution of another type of assay, one 
for which 4-nitrophenyl-α-D-glucopyranoside (PNP-glucose) was used as the substrate. 
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Figure 7.  Chemical structures of maltose (10), palatinose (11), and PNP-glucose (12).  
Images adapted from http://www.sigmaaldrich.com. 
The ultimate purpose of this work is to provide a detailed analysis of inhibition of 
mammalian small intestinal α-glucosidases by the polyhydroxylated pyrrolidine inhibitors LAB-
1 and DAB-1.  By using purified recombinant SI and MGAM subunits, it is possible to more 
precisely describe the mechanisms by which these two inhibitors exert their effects.  This 
information will contribute to our scientific understanding of pyrrolidine iminosugars and their 
roles as α-glucosidase inhibitors. 
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Chapter 2 Materials and Methods 
 
2.1 Assays for inhibition of maltose hydrolysis 
 
 
Unless otherwise indicated, all chemicals were sourced from Sigma-Aldrich. 
Each assay for maltase activity was performed in two 96-well microtitre plates, adapted 
from the method of Arne Dahlqvist (Dahlqvist, 1961).  Completion of the assay depended on 
several sequential reactions: an initial hydrolysis reaction, and a subsequent series of reactions 
for development of a secondary chromophoric product.  The assay’s first step involved the 
hydrolytic cleavage of maltose to two glucose molecules in the presence of MGAM or SI.  This 
reaction is represented by Equation 7.   
  
Equation 7.  Hydrolysis of maltose by MGAM or SI. 
 Images adapted from http://www.sigmaaldrich.com. 
 
Before addition to the reaction mixture, maltose was dissolved in a buffer containing 200 
mM MES monohydrate at pH 6.5.   The reaction was immediately incubated at 37°C, and had a 
final reaction volume of 50 µL.  The reaction time was 45 minutes.  Enzyme stocks contained 10 
mM NaCl and 20 mM Tris, at pH 8; stocks were highly diluted (1:100 to 1:500) with Milli-Q™ 
water before use in assays.  Variable quantities of each recombinant subunit were added; these 
quantities are recorded in Table 1.  Any inhibitors added to the reaction were dissolved in 200 
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mM MES monohydrate, pH 6.5.  The total reaction volume was divided up as follows: 10 µL 
enzyme, 10 µL inhibitor, and 30 µL substrate. 
 
Table 1.  Enzyme quantities used in assays for inhibition of maltase activity. 
Catalytic Subunit Quantity Added to Reaction (ng) 
Nt-SI 6.7 
Ct-SI 5.0 
Nt-MGAM 10 
Ct-MGAM N2 2.0 
Ct-MGAM N20 6.7 
 
The range of substrate concentrations tested in each assay was tailored to each catalytic 
subunit; ideal ranges were determined by trial and error.  This was done to ensure fair 
representation of both linear and plateau regions of Michaelis-Menten curves and to improve 
estimates of kinetic parameters Km (mM) and Vmax (molL
-1s-1).  Inhibitor concentration ranges 
were also adjusted to improve resolution of inhibitory effects; ranges spanned from 15-200 nM 
to 1.2-8 µM, depending on which enzyme-substrate pair was used. 
Upon completion of the first incubation period, assay microplates were removed to room 
temperature.  The first reaction was quenched using 25 µL of a buffer containing 3M Tris, pH 
6.9.  A mixture of reduced o-dianisidine and the enzyme glucose oxidase-peroxidase (Dahlqvist, 
1961), with a total volume of 125 µL, was added to initiate the second reaction, described by 
Equation 8.  Microplates were immediately incubated at 37 degrees Celsius. 
 
Glucose + H2O + O2  D-Gluconic Acid + H2O2 
Equation 8.  Oxidation of glucose by glucose oxidase-peroxidase.  
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 Formation of H2O2 allowed another reaction to take place: H2O2 oxidized the reduced o-
dianisidine to form oxidized o-dianisidine, a brown-coloured product detectable by 
spectrophotometer at 450 nm.  On the same microplates used for the assay, a glucose standard 
curve was included and used to calculate glucose liberated over the total reaction time of 45 
minutes.  Quadruplicate absorbance values for each data point were used to determine glucose 
concentrations, and ultimately initial velocities for hydrolysis of maltose.  In this series of 
experiments, the rate was defined as molL-1s-1 of glucose developed over the course of the 
reaction.  Accounting for the stoichiometry of maltose hydrolysis, the real rate of the reaction 
was considered one-half of the rate of total glucose production. 
 
H2O2 + Reduced o-dianisidine  Oxidized o-dianisidine 
Equation 9.  Reaction of reduced o-dianisidine with hydrogen peroxide.  
 
All five enzymes, Nt-SI, Ct-SI, Nt-MGAM, Ct-MGAM N2, and Ct-MGAM N20, were 
tested in separate assays with the inhibitors LAB-1 and DAB-1.  The thiosugar sulfonium sulfate 
inhibitor salacinol was used as a positive control for inhibition of maltase activity.  No blank rate 
was observed over the range of maltose concentrations used in this assay. 
 
2.2 Assays for palatinose hydrolysis 
 
 
Assays involving palatinose as a substrate were performed following nearly identical 
methods to those described for maltase activity assays.  Methods that deviated from the maltase 
activity assay protocol are described as follows: 
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 Hydrolysis of palatinose liberates one glucose molecule, as indicated in Equation 
10.  When initial rates were calculated form absorbance data, this stoichiometry 
was taken into account. 
Palatinose  Glucose + Fructose 
Equation 10.  Hydrolysis of palatinose by MGAM or SI. 
 
 Enzyme quantities used in this series of assays are recorded in Table 2. 
 
Table 2.  Enzyme quantities used in assays for inhibition of palatinose hydrolysis. 
Catalytic Subunit Quantity Added to Reaction (ng) 
Nt-SI 67 
Nt-MGAM 200 
*C-terminal isoforms were not found to have any ability to hydrolyze palatinose. 
 
 A blank rate was observed for a negative control trial lacking enzyme.  This was 
presumed to be caused by a small amount of glucose contaminating the substrate, 
since the rate of glucose measured at the assay end point was directly proportional 
to the concentration of palatinose in solution. The blank rate was characterized 
and subtracted from rate data for all assays with palatinose as the substrate. 
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2.3 Assays for inhibition of PNP-glucose hydrolysis 
 
 
Assays with PNP-glucose involved only one reaction, since hydrolysis of this substrate 
produces equimolar amounts of glucose and nitrophenol.  PNP-glucose was dissolved in 200 mM 
MES monohydrate at pH 6.5.  Once again, substrate and inhibitor concentration ranges were 
tailored to individual enzymes for optimal representation and resolution of Michaelis-Menten 
plots.  Due to substrate solubility limitations, the maximum effective concentration of PNP-
glucose used in these assays was 30 mM. 
Importantly, only the deprotonated nitrophenolate ion is chromophoric, so upon 
completion of a 45-minute incubation period, the reaction was stopped and alkaline conditions 
were introduced via the addition of 150 µL of 500 mM sodium bicarbonate buffer, pH 10.  
Microplates were read by spectrophotometer at 405 nm.    
 
PNP-Glucose  Glucose + 4-Nitrophenol 
Equation 11.  Hydrolysis of PNP-glucose by MGAM or SI. 
  
 Enzyme quantities used in PNP-glucose hydrolysis assays are recorded in Table 3. 
 
Table 3.  Enzyme quantities used in assays for inhibition of PNP-glucose hydrolysis. 
Catalytic Subunit Quantity Added to Reaction (ng) 
Nt-SI 83 
Ct-SI 250 
Nt-MGAM 100 
Ct-MGAM N2 330 
Ct-MGAM N20 330 
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2.4 Nickel column purification of Ct-MGAM N2 and N20 
 
Purification of Ct-MGAM N20 and Ct-MGAM N2 was performed by affinity 
chromatography using a nickel-NTA column.  Methods for purification of these two proteins 
were identical.  Ct-MGAM subunits were expressed individually from Baculovirus constructs in 
High Five insect cells at the Baylor College of Medicine in Houston, Texas.   C-terminal His-
tagged Ct-MGAM was secreted from insect cells into liquid media.  Media was centrifuged for 
30 minutes at 9000 RPM and the supernatant, containing secreted soluble proteins, was decanted 
into a sterile flask.  After this, the supernatant was vacuum-filtered through a 500 mL Rapid-
Flow™ filter unit with a 0.1 µm aPES membrane.  The supernatant underwent overnight batch 
binding with HisPur™ Ni-NTA resin from ThermoScientific, Inc. (4 mL of resin per 500 mL of 
media).  Resin had been previously equilibrated using a buffer containing 300 mM NaCl and 50 
mM NaH2PO4, pH 8.  No imidazole was included during batch binding.  The resin was 
subsequently washed with two resin bed volumes of a buffer containing 10 mM imidazole, 300 
mM NaCl, and 50 mM NaH2PO4, pH 8.  A series of buffers containing increasing concentrations 
of imidazole (25 mM to 500 mM) were used to elute the target protein from a BioRad column, 
2.5 cm in diameter. 
Elutions containing Ct-MGAM N2 or N20 were concentrated to a volume of 5 mL using 
a 50K Amicon® Ultra centrifugal filter unit.  Next, the sample was subjected to a buffer 
exchange using 50K Amicon® Ultra microcentrifuge filter unit.  Protein was exchanged into a 
buffer containing 10 mM NaCl and 20 mM Tris, pH 8 and stored at -80 degrees Celsius. 
Ct-SI, Nt-SI, and Nt-MGAM preparations used in the present inhibition assays were all 
purified at an earlier date by Kyra Jones.  MGAM preparations are shown in Figure 8. 
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Figure 8.    MGAM preparations used for inhibition assays (14% denaturing gel) 
*Nt-MGAM was purified by Kyra Jones 
** All assays with Ct-MGAM N2, except for the assay involving DAB-1 and PNP-glucose, were 
performed using the preparation indicated here.  The second preparation is indicated in 
Appendix I. 
 
  
Figure 9 contains SDS-PAGE photos for SI preparations. 
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Figure 9.    SI preparations used for inhibition assays (14% denaturing gel) 
*Both Ct-SI and Nt-SI were purified by Kyra Jones 
 
 
2.5 Inhibition assay data analysis 
 
 
Nonlinear curve fitting for substrate inhibition plots was performed using 
KaleidaGraph™ software from Synergy Software; curves were fit using the Levenberg-
Marquardt algorithm (a Damped Least Squares method).  All inhibition assay data analysis was 
performed using the SigmaPlot Version 13.0 Enzyme Kinetics module (Systat Software, San 
Jose, CA).  When global curve fitting did not yield sufficiently unambiguous results, local curve 
analyses were performed using KaleidaGraph™ software. 
 Rate equations for full and partial competitive, noncompetitive, and mixed inhibition 
systems are included on the following page. 
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Equations 12-17 (Segel, 1975): 
 
Full Competitive:                                      
𝑣
𝑉𝑚𝑎𝑥
=
[𝑆]
𝐾𝑚(1+ 
[𝐼]
𝐾𝑖
)+[𝑆]
 
Full Noncompetitive:                                
𝑣
𝑉𝑚𝑎𝑥
=
[𝑆]
𝐾𝑚(1+ 
[𝐼]
𝐾𝑖
)+[𝑆](1+ [𝐼]𝐾𝑖
)
 
Full Mixed-type:                                       
𝑣
𝑉𝑚𝑎𝑥
= 
[𝑆]
𝐾𝑚(1+
[𝐼]
𝐾𝑖
)+[𝑆](1+
[𝐼]
𝛼𝐾𝑖
)
  
Partial Competitive:                                  
𝑣
𝑉𝑚𝑎𝑥
=  
[𝑆]
𝐾𝑚
(1+
[𝐼]
𝐾𝑖
)
(1+
[𝐼]
𝛼𝐾𝑖
)
+[𝑆]
 
Partial Noncompetitive:                            
𝑣
𝑉𝑚𝑎𝑥
= 
[𝑆]
𝐾𝑚
(1+
[𝐼]
𝐾𝑖
)
(1+
𝛽[𝐼]
𝐾𝑖
)
+[𝑆]
(1+
[𝐼]
𝐾𝑖
)
(1+
𝛽[𝐼]
𝐾𝑖
)
 
Partial Mixed-type:                                   
𝑣
𝑉𝑚𝑎𝑥
=  
[𝑆]
𝐾𝑚
(1+
[𝐼]
𝐾𝑖
)
(1+
𝛽[𝐼]
𝛼𝐾𝑖
)
+[𝑆]
(1+
[𝐼]
𝛼𝐾𝑖
)
(1+
𝛽[𝐼]
𝛼𝐾𝑖
)
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Chapter 3 Results and Discussion 
 
3.1 Kinetic parameters for hydrolysis of maltose, palatinose, and  
PNP-glucose 
 
Replicates of all hydrolysis assays were performed with no inhibitor present in order to 
establish Michaelis constants for different enzyme-substrate combinations.  Km values were 
determined and compared with literature values where possible. 
 
 
3.1.1 Kinetic parameters for hydrolysis of maltose and PNP-glucose 
  hjjh 
 Kinetic parameters for hydrolysis of maltose and PNP-glucose were obtained by 
nonlinear regression of rate data from spectrophotometric experiments using KaleidaGraph™ 
software.  Table 4 illustrates Km, kcat, and kcat/Km values obtained from maltose hydrolysis assays 
with no inhibitor present. 
 
Table 4.  Kinetic parameters for α-glucosidases with maltose substrate 
†
Enzyme-Substrate Pair Km (mM) ‡ kcat (s
-1) ‡ kcat/Km (s-1mM-1) 
7 Nt-SI & Maltose 6.58 +/- 0.76 26.8 +/- 3.7 4.1 
13 Ct-SI & Maltose 5.42 +/- 0.20 24.9 +/- 2.1 4.6 
7 Ct-MGAM N2 & Maltose 0.858 +/- 0.076 32.4 +/- 8.2 37.8 
10 Ct-MGAM N20 & Maltose 2.01 +/- 0.18 27.4 +/- 7.6 13.6 
8 Nt-MGAM & Maltose 4.59 +/- 0.29 9.5 +/- 1.8 2.1 
† Number of trials in each average is indicated in superscript 
‡ Error is reported as a standard error of the mean 
 
 
 Kinetic parameters for hydrolysis of PNP-glucose are reported Table 5. 
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Table 5.  Kinetic parameters for α-glucosidases with PNP-glucose substrate 
†
Enzyme-Substrate Pair Km (mM) ‡ kcat (s
-1) ‡ kcat/Km (s-1mM-1) 
4 Nt-SI & PNP-Glucose 2.32 +/- 0.055 2.3 +/- 0.2 1.01 
5 Ct-SI & PNP-Glucose 8.18 +/- 0.76 0.4 +/- 0.08 0.05 
3 Ct-MGAM N2 & PNP-Glucose 2.35 +/- 0.80 0.3 +/- 0.1 0.13 
4 Ct-MGAM N20 & PNP-Glucose 3.48 +/- 0.34 0.1 +/- 0.01 0.03 
3 Nt-MGAM & PNP-Glucose 16.7 +/- 2.4 1.9 +/- 0.3 0.11 
† Number of trials in each average is indicated in superscript 
‡ Error is reported as a standard error of the mean 
 
3.1.2 Inhibition constants associated with maltose and PNP-glucose hydrolysis by 
mammalian α-glucosidases in the presence of LAB-1 and DAB-1. 
 
Table 6 contains results for inhibition assays involving LAB-1, the separate substrates 
maltose and PNP-glucose, and all five catalytic subunits.  Both mixed and competitive modes of 
inhibition were observed in the presence of LAB-1.  The mode of inhibition associated with each 
substrate depended on the catalytic subunit under observation.  Presence or absence of mixed 
inhibition, and the extent thereof, also appeared to be influenced by the substrate used.   
 
Table 6.  Inhibition constants for LAB-1 with mammalian α-glucosidases 
Enzyme-Substrate Pair Ki (nM) α β 
Mode of 
Inhibition 
Nt-SI & PNP-Glucose 56.6 +/- 8.7 10.70 +/- 4.76  - Mixed 
Nt-SI & Maltose 29.8 +/- 2.5 6.05 +/- 1.30 - Mixed 
Ct-SI & PNP-Glucose 565 +/- 30 - - Competitive 
Ct-SI & Maltose 608 +/-  51 10.96 +/- 2.60 - Mixed 
Nt-MGAM & PNP-Glucose 560 +/- 55 7.96 +/- 3.49 - Mixed 
Nt-MGAM & Maltose 413 +/- 33 - - Competitive 
Ct-MGAM N2 & PNP-Glucose 312 +/- 32 3.42 +/- 0.488 - Mixed 
Ct-MGAM N2 & Maltose 411 +/- 63 4.39 +/- 0.987 - Mixed 
Ct-MGAM N20 & PNP-Glucose 573 +/- 46 - - Competitive 
Ct-MGAM N20 & Maltose 463 +/- 40 4.46 +/- 0.625 - Mixed 
† Error in each parameter is reported as a standard error of the mean 
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Likewise, results for assays involving DAB-1 are reported in Table 8.  Once again both 
mixed and competitive inhibition kinetics are observed for different enzyme-substrate pairs in 
the presence of this inhibitor.  Inhibition constants are consistently larger in magnitude for DAB-
1 than for LAB-1, indicating that all five subunits have a generally weaker affinity for the D-
enantiomer. 
 
Table 7.  Inhibition constants for DAB-1 with mammalian α-glucosidases 
Enzyme-Substrate Pair Ki (µM) α β 
Mode of 
Inhibition 
Nt-SI & PNP-Glucose 1.18 +/- 0.113 13.25 +/- 3.57  - Mixed 
Nt-SI & Maltose 0.500 +/- 0.039 9.47 +/- 2.54 - Mixed 
Ct-SI & PNP-Glucose 5.16 +/- 0.409 - - Competitive 
Ct-SI & Maltose 4.95 +/- 0.266 - - Competitive 
Nt-MGAM & PNP-Glucose 3.43 +/- 0.120 - - Competitive 
Nt-MGAM & Maltose 1.82 +/- 0.171 8.75 +/- 2.06 - Mixed 
Ct-MGAM N2 & PNP-Glucose 2.717 +/- 0.183 8.43 +/- 1.11 - Mixed 
Ct-MGAM N2 & Maltose 2.64 +/- 0.353 6.53 +/- 1.44 - Mixed 
Ct-MGAM N20 & PNP-Glucose 4.82 +/- 0.032 8.55 +/- 0.693 - Mixed 
Ct-MGAM N20 & Maltose 2.80 +/- 0.223 14.11 +/- 2.78 - Mixed 
† Error in each parameter is reported as a standard error of the mean 
 
Results from inhibition assays with palatinose as substrate are excluded here due to the 
occurrence of substrate inhibition.  LAB-1 and DAB-1 were both found to inhibit palatinose 
hydrolysis by Nt-SI and Nt-MGAM, but mechanistic deductions were not made due to overlap 
between the range of substrate concentrations used in the inhibition assays, and the range of 
substrate concentrations that elicited the phenomenon of substrate inhibition. 
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3.2     Substrate inhibition of palatinose hydrolysis by Nt-SI and Nt-MGAM 
 
Substrate inhibition occurs at elevated substrate concentrations when increasing the 
concentration of substrate in solution leads to a reduced rate of reaction.  At the molecular level, 
it is generally caused by the formation of enzyme-substrate-substrate (ESS) complexes with 
reduced or abolished catalytic activity (Purich, 1983).  There are several mechanisms by which 
substrate inhibition can occur: it can be caused by the presence of a second binding site of lower 
substrate affinity; it may also commonly result from a second substrate molecule binding to a 
subsite in an already partially occupied binding pocket (Purich, 1983).  In the second scenario, 
two substrate molecules can bind simultaneously in sub-optimal configurations.  Resultant ESS 
complexes may be entirely nonproductive, or they may retain some catalytic activity. 
Nt-SI’s capacity to hydrolyze palatinose was tested using a broad range of substrate 
concentrations.  The palatinose hydrolysis activity assay was performed as described previously.  
Subtracting the blank rate observed from the control with no enzyme present was very important, 
especially at higher substrate concentrations.  The blank rate was thought to be caused by 
contaminating glucose in the substrate.  Although the substrate was greater than 99% pure, at 
very high concentrations, contaminants could be present in significant quantities.  The blank rate, 
determined to be linear with respect to the concentration of palatinose in solution, was subtracted 
from rates obtained from the assay in question in order to isolate the changes in reaction rate that 
were solely due to the substrate inhibition phenomenon. 
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Figure 10.  Partial substrate inhibition model for Nt-SI hydrolysis of palatinose.  Error bars 
represent the standard error of the mean. 
 
 
 
Results of this assay indicate that at a concentration of approximately 50 mM palatinose, 
substrate inhibitory effects begin to take place.  Data were first fit to a partial substrate inhibition 
model by nonlinear regression with Kaleidagraph™ software.  For this model, the coefficient of 
determination was 0.998.  The rate equation, originally derived by J. B. S. Haldane in 1930 
(Haldane, 1930), was obtained from Herbert J. Fromm’s publication Initial Rate Enzyme 
Kinetics: 
𝑣 =
𝑉1 ∙ [1 +
𝑉2 ∙ [𝑆]
𝑉1 ∙ 𝐾𝑖
]
1 +
𝐾𝑚
[𝑆]
+
[𝑆]
𝐾𝑖
 
Equation 18.  Partial substrate inhibition rate equation (Fromm, 1975). 
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A model for complete substrate inhibition was also considered.  The rate equation for this 
model is 
𝑣 =
𝑉1 ∙ [𝑆]
𝐾𝑚 + [𝑆] +
[𝑆]2
𝐾𝑖
 
Equation 19.  Complete substrate inhibition rate equation (Fromm, 1975). 
 
The complete substrate inhibition model was also an excellent fit, with a coefficient of 
determination of 0.997. 
 
Figure 11.  Complete substrate inhibition model for Nt-SI hydrolysis of palatinose. 
 
Since the partial substrate inhibition model does not provide a significantly better fit to 
the data, it is more likely that the substrate inhibition seen here is complete.  Based on structural 
evidence for multiple subsites within the Nt-SI active site (Sim et al., 2010), the possibility that 
multiple palatinose molecules are able to bind the enzyme should be considered.  Because there 
is no evidence for presence of a second, lower-affinity binding site for palatinose or other 
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disaccharide substrates, the concomitant binding of two palatinose molecules to the active site is 
the preferred hypothesis.   
Assuming that the substrate inhibition is complete, the Michaelis constant for the ES (Nt-
SI-palatinose) complex is 14.28 mM, while the dissociation constant for the ESS complex is 
110.58 mM.  A complete substrate inhibition model assumes that as the substrate concentration 
becomes infinitely high, the rate of reaction will approach zero. 
The substrate inhibition seen here is possibly related to the fact that the natural substrate 
of Nt-SI is isomaltose, a disaccharide composed of glucose subunits which is, like palatinose, 
linked by an α-1,6 glycosidic bond; of the other catalytic subunits, isomaltase activities have 
only been observed for Nt-MGAM, and to a much lesser extent (Lee et al., 2014).  Palatinose 
concentrations that elicit this kinetic behaviour are higher than one would generally expect to 
find in the small intestine under physiological conditions.  For this reason, it is quite possible that 
this substrate inhibition is a phenomenon without great biological significance.  It may simply be 
a product of in vitro experimental conditions which do not properly reflect the conditions these 
enzymes would normally encounter in the mammalian small intestine. 
Neither partial nor complete substrate inhibition was observed for any C-terminal 
catalytic subunits and substrates studied here.  Some evidence for substrate inhibition has been 
observed for Nt-MGAM, although the phenomenon remains to be fully characterized.  
Preliminary data were modeled using the complete substrate inhibition equation (Equation 13).  
Based on this model, the Michaelis constant for Nt-MGAM hydrolysis of palatinose is estimated 
to be 110.89 mM, and the dissociation constant for the ESS complex is estimated to be 278.68 
mM.   
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Figure 12.  Complete substrate inhibition model for Nt-MGAM hydrolysis of palatinose. 
 One possible explanation for substrate inhibition in this case is that both the -1 and +1 
subsites are occupied respectively by glucose or fructose moieties of two palatinose molecules.  
For Nt-SI, substrate inhibitory effects appear to begin taking place at much lower concentrations 
of palatinose than they do for Nt-MGAM, mirroring the difference in Michaelis constants 
observed for the two enzymes with this substrate.   
 
Table 8.  Kinetic parameters for Nt-SI and Nt-MGAM with palatinose substrate 
 
Enzyme-Substrate Pair K
m (mM)  Vmax (molL
-1s-1) Ki (mM) 
Nt-SI & PNP-Glucose 14.28 +/- 1.27 7.1x10
-8 +/- 3.4x10-9 110.58 +/- 9.94 
Nt-MGAM & PNP-Glucose 110.89 +/- 20.6  9.7x10
-9 +/- 1.2 x10-9 278.68 +/- 63.6 
 sd 
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3.3 Inhibition of Nt-SI activities by LAB-1 
 
3.3.1 Inhibition of Nt-SI maltose hydrolysis by LAB-1 
 
Concerning the hydrolysis of maltose, LAB-1 and DAB-1 both inhibit Nt-SI more 
effectively than they inhibit any of the other catalytic subunits.  The Ki value associated with 
inhibition by LAB-1, 29.8 +/- 2.5 nM, indicates the most potent inhibition observed in any 
experiments reported here.  A physical interpretation of this number is that the inhibitor is able to 
interact with Nt-SI in a manner that influences the enzyme’s ability to bind the substrate maltose.  
Presumably, when LAB-1 binds to Nt-SI, an EI complex forms, decreasing the amount of free 
enzyme present.  Based on this event, a shift in the chemical equilibrium causes ES complexes 
present in the reaction mixture to more readily dissociate back to free enzyme and free substrate.  
The apparent or observed Michaelis constant is increased in the presence of this inhibitor, as a 
result.  A substantial increase in Km
app, dependent on inhibitor concentration, was seen in the 
presence of LAB-1.  The Michaelis-Menten plot for this inhibition assay is illustrated in Figure 
13.  
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Figure 13. Michaelis-Menten plot for Nt-SI hydrolysis of maltose in the presence of LAB-1. 
 
These data indicated that the inhibitor concentration affected not only on the apparent 
Michaelis constants, but also the apparent maximal reaction velocity.  The apparent Vmax was 
decreased in the presence of LAB-1, indicating that this inhibitor and the maltose substrate could 
be bound to Nt-SI simultaneously.  SigmaPlot’s Enzyme Kinetics module was used for a global 
assessment of the family of curves.  A full mixed inhibition model for data collected at variable 
LAB-1 concentrations provided the best fit, ranked first among all kinetic models under 
consideration, with a coefficient of determination of 0.987.  Full and partial models for 
competitive, mixed, and noncompetitive inhibition were all analyzed; uncompetitive models 
were excluded on the basis of a very unambiguous increase in magnitude of the parameter Km in 
the presence of LAB-1.  Full competitive and noncompetitive models yielded respective 
coefficients of determination of 0.925 and 0.969.  Based on these findings, it appears that either 
this inhibitor can bind the ES complex, or the substrate can bind the EI complex, or both, causing 
the formation of a non-productive EIS complex. 
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The following double-reciprocal Lineweaver-Burk plot was also constructed.  Lines of 
the Lineweaver-Burk plot provided a fair fit for the data.  Lines were found to intersect very 
close to but slightly to the left of the ordinate axis.  Noticeably higher error was observed for 
data points which were calculated from the lowest absorbance readings, due to poor 
spectrophotometer sensitivity at low concentrations of the chromophoric product. 
             
Figure 14. Lineweaver-Burk plot for Nt-SI hydrolysis of maltose in the presence of LAB-1. 
 
The possibility of formation of a productive EIS complex, indicating partial inhibition, 
was explored via transformation of the data for use in a Dixon plot.  This plot illustrates changes 
in the reciprocal rate of reaction over a range of inhibitor concentrations.  When a compound 
causes complete inhibition, it is expected that the change in the reciprocal rate is linear with 
respect to a change in the inhibitor concentration.  A hyperbolic Dixon plot indicates that at 
higher inhibitor concentrations, an increase in the inhibitor concentration has much smaller 
effects on the rate than it does at lower inhibitor concentrations.  This can be explained by the 
formation of a productive EIS complex.  
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Figure 15.  Dixon plot for Nt-SI hydrolysis of maltose in the presence of LAB-1. 
Linearity of Dixon plot data points for each substrate concentration indicate that 
inhibition by LAB-1 is complete rather than partial.  Lines appear to intersect at a point with an 
abscissa of approximately -30 nM.  This indicates a Ki value of this magnitude. 
Catalytic effects of LAB-1 binding are possibly due to a number of interactions with Nt-
SI residues proximal to the -1 subsite.  Considering the crystal structure of Nt-SI complexed with 
kotalanol, it is apparent that acid/base catalyst Asp 571 and catalytic nucleophile Asp 472 (Sim 
et al., 2010) may both be interacting with LAB-1, if its binding configuration is at all similar to 
that of the five-member ring of kotalanol.  LAB-1 may be only partially obstructing the -1 
subsite, allowing maltose to still bind, while its hydrogen bonding interaction with Asp 571 
and/or Asp 472 may prevent effective catalysis.  Asp 355 may also interact with LAB-1 if it 
binds in the -1 subsite.  To implicate a complete and accurate set of residues involved in binding 
LAB-1, a crystal structure of Nt-SI in complex with this inhibitor is needed. 
 
48 
 
3.3.2 Inhibition of Nt-SI PNP-glucose hydrolysis by LAB-1 
 
The assay conducted to assess the extent of Nt-SI hydrolysis of PNP-glucose in the 
presence of LAB-1 yielded data which were, like those obtained from the experiment with 
maltose, best explained by a mixed-type inhibition model.  The global analysis performed using 
SigmaPlot’s Enzyme Kinetics module indicated that a partial mixed model was the best fit, with 
a coefficient of determination of 0.968.  The full mixed model had a coefficient of determination 
of 0.965.  Due to the small difference in goodness of fit of the two models, linearity of the Dixon 
plot was assessed qualitatively as well.  The greater value of R2 observed for the partial mixed 
model might simply have been caused by the addition of a redundant parameter (Motulsky, 
2014).  Evidence for hyperbolic character of lines in the Dixon plot would support the case for a 
partial mixed model.  Dixon plots were therefore carefully considered. 
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Figure 16.  Michaelis-Menten and Dixon plots for Nt-SI hydrolysis of PNP-glucose in the 
presence of LAB-1; a) Michaelis-Menten plot for full mixed model, b) Michaelis-Menten 
plot for partial mixed model, c) Dixon plot for full mixed model, d) Dixon plot for partial 
mixed model. 
 
Both full and partial mixed model Dixon plots appear to fit data points fairly well.  Data 
points from the assay trial at 200 nM LAB-1 appear in some cases to have lower reciprocal rates 
than the full mixed model would predict.  The partial mixed model provides a better fit for the 
0.5 mM PNP-glucose point at 200 nM LAB-1.  However, this model also provides a poorer fit 
for other data points, and altogether, these qualitative observations of the Dixon plots do not 
justify an increase in model complexity.  It is possible that the apparent hyperbolic character is 
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an artifact of the assay procedure, especially since it mainly appears to be due to 200 nM LAB-1 
data points alone. 
Table 9.  Kinetic parameters for partial and full mixed models of LAB-1 inhibition of PNP-
glucose hydrolysis by Nt-SI. 
Model K
m (mM) Ki (nM) α β R
2 
Partial Mixed 2.4 +/- 0.2  54.3 +/- 11.8 5.2 +/- 2.0 0.44 +/- 0.14 0.968 
Full Mixed 2.2 +/- 0.2 56.6 +/- 8.7 10.7 +/- 4.8 - 0.965 
  Error in all columns is reported as a standard error of the mean 
 
Assuming a full mixed inhibition model, the Ki is 56.6+/- 8.7 nM, and the value of the 
parameter α is 10.7.  Invoking the principle of parsimony, and due to its general goodness of fit, 
this remains the preferred model.  Furthermore, a replot of Km
app/Vmax
app as a function of LAB-1 
concentration was an excellent fit to a linear model, providing no compelling evidence for a 
partial inhibition. 
 
Figure 17.  Replot of Kmapp / Vmaxapp as a function of [LAB-1] for LAB-1 inhibition of PNP-
glucose hydrolysis by Nt-SI. 
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3.4 Inhibition of Ct-SI activities LAB-1 
 
3.4.1 Inhibition of Ct-SI maltose hydrolysis by LAB-1 
 
Inhibition of Ct-SI maltose hydrolysis by LAB-1 was best suited to a full mixed 
inhibition model.  The inhibition constant was found to be 0.608 +/- 0.051 µM, and the 
parameter α was 10.96 +/- 2.60.  A full mixed inhibition model would suggest that LAB-1 is able 
to bind to both the free enzyme and to the ES complex, exerting effects on the apparent affinity 
Ct-SI has for maltose, as well as on Ct-SI’s catalytic capacity. 
            
 
Figure 18.  Michaelis-Menten, Lineweaver-Burk, and Dixon plots for Ct-SI hydrolysis of 
maltose in the presence of LAB-1, assuming a full mixed inhibition model; a) Michaelis-
Menten plot, b) Lineweaver-Burk plot, c) Dixon plot. 
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60 mM maltose data points do not conform as well to this model as the lower substrate 
concentration data points.  This is obvious when one observes both Michaelis-Menten and Dixon 
plots.  The coefficient of determination for the full mixed inhibition model was 0.982.  While 
once again a partial mixed model was ranked highest by R2, a distinct lack of evidence for 
hyperbolic character in the Dixon plot indicates that a full inhibition model provides the most 
suitable explanation for these data. 
In a local analysis, estimation of kinetic parameters for individual curves by nonlinear 
regression does not show a significant change in Vmax in the presence of LAB-1, and the 
Lineweaver-Burk plot produced from these data indicates competitive inhibition.  That results 
obtained by the global analysis should contrast those obtained by the individual curve analysis 
seems counterintuitive.  The standard error of the mean for each data point clearly does not 
account for the apparent displacement of points at 60 mM maltose, so it is unlikely that this is 
simply an inflated experimental error.  Conclusions from the global analysis will be reported 
here, but reasonable uncertainty in the mode of inhibition should be duly noted. 
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3.4.2 Inhibition of Ct-SI PNP-glucose hydrolysis by LAB-1 
LAB-1 was found to competitively inhibit PNP-glucose hydrolysis by Ct-SI.  The full 
competitive model was ranked highest by R2, with a value of 0.989.  The inhibition constant 
determined from these data was 0.565 +/- 0.030 µM.  This value was very similar to that 
obtained from the assay with Ct-SI, LAB-1, and maltose, at 0.608 +/- 0.051 µM. 
 
 
Figure 19.  Michaelis-Menten and Lineweaver-Burk plots for Ct-SI hydrolysis of PNP-
glucose in the presence of LAB-1, assuming a full competitive inhibition model; a) 
Michaelis-Menten plot, and b) Lineweaver-Burk plot. 
 
The difference in modes of inhibition between Nt-SI (mixed) and Ct-SI (competitive) in 
the presence of PNP-glucose implies that, while Nt-SI can apparently accommodate LAB-1 and 
PNP-glucose binding simultaneously, Ct-SI cannot.  Without structural information about the Ct-
SI active site, it is difficult to detail the molecular interactions that may lead to this result.  It is 
possible, however, that the shape of the Nt-SI +1 subsite, which is known to be narrower and 
more spatially constraining than the Nt-MGAM subsite (Sim et al., 2010), is instrumental in 
determining whether PNP-glucose and LAB-1 can bind simultaneously. 
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3.5 Inhibition of Nt-MGAM activities LAB-1 
 
3.5.1 Inhibition of Nt-MGAM maltose hydrolysis by LAB-1 
 
LAB-1 was found to inhibit Nt-MGAM maltose hydrolysis competitively (R2 = 0.979), 
with a Ki value of 0.413 +/- 0.033 µM.  Please see Figure 20 for Michaelis-Menten and 
Lineweaver-Burk plots. 
 
 
Figure 20.  Michaelis-Menten and Lineweaver-Burk plots for Nt-MGAM hydrolysis of 
maltose in the presence of LAB-1 with full competitive inhibition model; 
a) Michaelis-Menten plot and b) Lineweaver-Burk plot. 
 
Of the other catalytic subunits, Nt-SI has the highest overall amino acid sequence 
similarity to Nt-MGAM (Sim et al., 2010), and the -1 subsites of the two enzymes’ active sites 
share many structural features essential to the hydrolysis of substrates such as maltose and PNP-
glucose (Sim et al., 2010).  Mixed inhibition kinetics observed for Nt-SI and LAB-1 indicate that 
LAB-1 binds both to Nt-SI and to the Nt-SI-maltose complex, with a marked preference for the 
free enzyme.  Nt-MGAM, however, does not seem to tolerate the simultaneous binding of both 
maltose and LAB-1.  It is logical that if LAB-1 binds in a manner similar to the five-member 
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ring of kotalanol near the -1 subsite, structural differences in this immediate region should be 
able to contribute to a hypothesis that would explain the kinetic disparities. 
The most pronounced difference in the -1 subsites of these two enzymes is that Nt-SI’s 
Tryptophan 327 is analogous to Tyrosine 299 in Nt-MGAM (Sim et al., 2010).  Trp 327 in Nt-SI 
is thought to confer α-1,6 specificity (Sim et al., 2010).  This residue may be integral to the 
determination of whether one or both ligands can bind the -1 subsite at once.  Differences in the 
+1 subsite may also be important; constraints placed on the substrate from the narrowness of the 
Nt-SI +1 subsite, compared with the Nt-MGAM +1 subsite (Sim et al., 2010), might actually be 
necessary for it to bind in the presence of LAB-1. 
 
 
3.5.2 Inhibition of Nt-MGAM PNP-glucose hydrolysis by LAB-1 
A number of models provided excellent fits to data from the LAB-1 inhibition assay with 
Nt-MGAM and PNP-glucose.  A partial mixed inhibition model was considered to be the best fit 
(R2 = 0.992) and a full mixed model appeared to fairly explain the data as well (R2 = 0.979).    
Dixon plots were used to compare the full and partial models qualitatively.  
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Figure 21.  Michaelis-Menten and Dixon plots for Nt-MGAM hydrolysis of PNP-glucose in 
the presence of LAB-1; a) Michaelis-Menten plot for full mixed model, b) Michaelis-
Menten plot for partial mixed model, c) Dixon plot for full mixed model, d) Dixon plot for 
partial mixed model. 
 
In addition to both mixed models, competitive and noncompetitive models were also 
assessed.  The partial competitive model provided a very poor fit for 2 mM PNP-glucose data 
points on the Dixon plot, and the full competitive model had a lower coefficient of determination 
than both mixed models.  Noncompetitive models were globally poor fits. 
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Table 10.  Kinetic parameters for partial and full mixed models of LAB-1 inhibition of 
PNP-glucose hydrolysis by Nt-MGAM. 
Model K
m (mM) Ki (µM) α β R
2 
Partial Mixed 15.2 +/- 0.8  0.560 +/- 0.055 4.49 +/- 0.95 0.43 +/- 0.072 0.992 
Full Mixed 13.5 +/- 1.0 0.560 +/- 0.048 7.96 +/- 3.49 - 0.979 
  Error in all columns is reported as a standard error of the mean 
Assuming a full mixed model, Ki was found to be 0.560 +/- 0.055 µM, with an α value of 
7.96 +/- 3.49.   For the partial mixed model, the inhibition constant was 0.560 +/- 0.048 µM.  
Parameters α and β were 4.49 +/- 0.95 and 0.43 +/- 0.072, respectively.  To further investigate 
the possibility of hyperbolic inhibition, a secondary replot was constructed, considering Km
app
 / 
Vmax
app as a function of [LAB-1]. 
 
Figure 22.  Replot of Kmapp / Vmaxapp as a function of [LAB-1] for LAB-1 inhibition of PNP-
glucose hydrolysis by Nt-MGAM. 
 
The plot of Km
app
 / Vmax
app as a function of [LAB-1] was well explained by a linear model, 
with a coefficient of determination of 0.997.  Because the pattern of data points had no distinct 
hyperbolic character, introduction of a partiality factor into the rate equation was considered 
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unwarranted.  The full mixed model, albeit quantitatively a slightly poorer fit to the data, was 
therefore the preferred model. 
PNP-glucose solubility imposed an unfortunate limitation on this particular assay, 
resulting in sub-optimal representation of Michaelis-Menten curves.  With more accurate Vmax 
estimates, one would have more confidence that the full mixed model described here reflects the 
nature of the inhibition taking place.  
 
3.6 Inhibition of Ct-MGAM N2 and N20 activities by LAB-1 
 
3.6.1 Inhibition of Ct-MGAM N2 and N20 maltose hydrolysis by LAB-1 
 
The most suitable model for LAB-1 inhibition of Ct-MGAM N2 maltose hydrolysis was 
a full mixed model with a Ki value of 0.411 +/- 0.063 µM and an α value of 4.39 +/- 0.99.  
Michaelis-Menten and Lineweaver-Burk plots are depicted in Figure 23.  The full mixed model 
had a coefficient of determination of 0.945. 
Figure 23.  Michaelis-Menten and Lineweaver-Burk plots for Ct-MGAM N2 hydrolysis of 
maltose in the presence of LAB-1, assuming a full mixed inhibition model. 
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A partial mixed model was ranked first by R2 with a value of 0.947, but the Dixon plot 
for these data did not appear to conform well to the model.  The partial mixed model could not 
properly account for data points at 4000 nM [LAB-1].  Analysis of the Lineweaver-Burk plot for 
the partial mixed model also indicated a markedly poorer fit to most data points.  For these 
reasons, an additional increase in the complexity of the model was not justified.  All other 
models under consideration were poorer fits to the data, with R2 values of 0.91 or less. 
 
Figure 24.  Dixon plot for Ct-MGAM N2 hydrolysis of maltose in the presence of LAB-1, 
assuming a full mixed inhibition model. 
 
 
LAB-1 inhibition of Ct-MGAM N20 maltose hydrolysis was also most suited to a full 
mixed model (R2 = 0.98) with an inhibition constant of 0.463 +/- 0.040 µM and an α value of 
4.46 +/- 0.62.  There was no significant difference between inhibition constants and α values 
obtained from experiments with the two Ct-MGAM isoforms, indicating that they are not 
differentially inhibited by LAB-1. 
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The fact that there is no significant difference in the extent or mode of inhibition between 
the two C-terminal MGAM subunits suggests that the 89-amino acid substitution of Ct-MGAM 
N20 does not affect binding of LAB-1.  The -1 subsite of Ct-MGAM N2 has a number of 
proximal aspartic acid residues, including Asp 1420, Asp 1526 (potentially an acid/base 
catalyst), Asp 1279, and Asp 1157.  There are many opportunities for hydrogen-bonding with 
LAB-1 hydroxyl groups in this subsite.  Given the potential that Asp 1526 functions as an 
acid/base catalyst (Ren et al., 2011), the obstruction of catalysis might be explained by a contact 
between the inhibitor LAB-1 and this specific residue.  It is interesting, too, that this mode of 
inhibition is observed for nt-SI and both Ct-MGAM isoforms in the presence of maltose, while it 
is not observed for Nt-MGAM.   
 
 
Figure 25.  Michaelis-Menten and Lineweaver-Burk plots for Ct-MGAM N20 hydrolysis of 
maltose in the presence of LAB-1, assuming a full mixed inhibition model. 
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3.6.2 Inhibition of Ct-MGAM N2 and N20 PNP-glucose hydrolysis by LAB-1 
Data for LAB-1 inhibition of Ct-MGAM N2 PNP-glucose hydrolysis was best fit by a 
full mixed model, which yielded a Ki value of 0.312 +/- 0.032 µM and an α value of 4.39 +/- 
0.99 (R2 = 0.98).  These values are highly similar to mixed inhibition parameters determined for 
Ct-MGAM N2 and N20 hydrolysis of maltose in the presence of LAB-1.  This supports the 
conclusion that the two isoforms are affected to the same extent and most likely in the same way 
by the binding of LAB-1. 
 
Figure 26.  Michaelis-Menten and Lineweaver-Burk plots for Ct-MGAM N2 hydrolysis of 
PNP-glucose in the presence of LAB-1, assuming a full mixed inhibition model. 
 
LAB-1 inhibition of Ct-MGAM N20 PNP-glucose hydrolysis was best described by a full 
competitive inhibition model with a Ki value of 0.573 +/- 0.046 µM.  The model had a 
coefficient of determination of 0.985.  A partial mixed model was found to have higher R2 value 
(0.989), but the difference was not considered substantial enough to warrant introduction of an 
additional parameter.  The Dixon plot did not have any appreciable hyperbolic character.  
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The full competitive model fit high substrate concentration data points quite poorly, and 
for this reason, the possibility of mixed inhibition in this case was also explored.  An alternative 
analysis was performed whereby estimation of local kinetic parameters for individual curves was 
done by nonlinear regression.  The Lineweaver-Burk plot from this analysis also indicated 
competitive inhibition, as lines were found to intersect at the ordinate axis.  Based on a 
qualitative judgment, it is likely that the error associated with 25 mM substrate data points is due 
to experimental error.  The confidence associated with this conclusion is therefore rather low. 
 
 
 
3.7 Inhibition of Nt-SI activities by DAB-1 
 
3.7.1 Inhibition of Nt-SI maltose hydrolysis by DAB-1 
 
DAB-1 inhibition of Nt-SI maltose hydrolysis conformed well to a full mixed inhibition 
model (R2 = 0.98).  The inhibition constant was found to be 0.500 +/- 0.039 µM, and the α value 
was 9.47 +/- 2.54.  If a mixed model does fairly characterize these inhibition kinetics, then it 
should be concluded that LAB-1 and DAB-1 both reduce Nt-SI’s affinity for maltose and 
interfere with the mechanism of catalysis.  The Ki value associated with inhibition by LAB-1 is 
~17 times smaller in magnitude than the Ki value associated with inhibition by DAB-1, and 
catalytic effects caused by LAB-1 are also evidently more substantial.    
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Figure 27.  Michaelis-Menten and Lineweaver-Burk plots for Nt-SI hydrolysis of maltose in 
the presence of DAB-1, assuming a full mixed inhibition model. 
 
 The Dixon plot for these data revealed that 2 mM maltose data points conform rather 
poorly to the full mixed model.  Once again, increased error at low substrate concentrations is 
most likely the result of spectrophotometer error from low absorbance values.  Unsurprisingly, 
the error observed here is more pronounced at higher DAB-1 concentrations.  The Dixon plot 
provides good evidence for a full, rather than partial, inhibition model.   
 
3.7.2 Inhibition of Nt-SI PNP-glucose hydrolysis by DAB-1 
 
As was observed with the substrate maltose, DAB-1 inhibition of Nt-SI PNP-glucose 
hydrolysis is best described by a full mixed inhibition model (R2 = 0.981).  A partial mixed 
model was ranked first by R2 (R2 = 0.986), but there is not sufficient curvature in the Dixon plot 
to warrant an increase in model complexity.  Reciprocal rates associated with 4000 nM DAB-1 
data points on the Dixon plot are indeed generally lower than the full mixed model would 
predict, but this pattern does not appear to hold for data points associated with lower DAB-1 
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concentrations.  The full mixed model provided an inhibition constant of 1.18 +/- 0.113 µM and 
an α value of 13.25 +/- 3.57. 
 
                                       
 
Figure 28.  Dixon plot for Nt-SI hydrolysis of PNP-glucose in the presence of DAB-1, 
assuming a full mixed inhibition model. 
 
 
3.8 Inhibition of Ct-SI activities by DAB-1 
 
3.8.1 Inhibition of Ct-SI maltose hydrolysis by DAB-1 
 
The Ki value for DAB-1 inhibition of Ct-SI maltose hydrolysis was determined to be 4.95 
+/- 0.266, assuming a full competitive inhibition model (R2 = 0.988).  These inhibition kinetics 
are distinct from kinetics of LAB-1 inhibition, which were best suited to a full mixed model.  
The LAB-1 inhibition constant was ~8 times smaller in magnitude than that of DAB-1.   
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Figure 29.  Michaelis-Menten and Lineweaver-Burk plots for Ct-SI hydrolysis of maltose in 
the presence of DAB-1, assuming a full competitive inhibition model. 
 
3.8.2 Inhibition of Ct-SI PNP-glucose hydrolysis by DAB-1 
 
The best model for DAB-1 inhibition of PNP-glucose hydrolysis by Ct-SI was a partial 
mixed model (R2 = 0.986), with an inhibition constant of 2.37 +/- 0.302 µM.  Parameters α and β 
were determined to be 2.69 +/- 0.38 and 0.60 +/- 0.043, respectively.  This mode of inhibition is 
quite different from the full competitive model which best characterizes DAB-1 inhibition of 
maltose hydrolysis by Ct-SI.  A full competitive model was applied to these data as well, but the 
coefficient of determination was only 0.974.  Parameters associated with both full competitive 
and partial mixed models are reported below in Table 11. 
Table 11.  Kinetic parameters for partial mixed and full competitive models of DAB-1 
inhibition of PNP-glucose hydrolysis by Ct-SI. 
Model K
m (mM) Ki (µM) α β R
2 
Partial Mixed 5.4 +/- 0.3 2.37 +/- 0.30  2.69 +/- 0.38  0.60 +/-0.043  0.986 
Full Competitive 5.7 +/- 0.3  5.16 +/- 0.41  - - 0.974 
  Error in all columns is reported as a standard error of the mean 
Michaelis-Menten plots are depicted in Figure 30. 
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Figure 30.  Michaelis-Menten plots for Ct-SI hydrolysis of PNP-glucose in the presence of 
DAB-1; a) partial mixed model, and b) full competitive model. 
 
Dixon plots for partial and full mixed inhibition models were also compared.  Points on 
the Dixon plot are fit better by the partial mixed model, but the difference in goodness of fit may 
simply be due to generally higher error associated with points obtained at low substrate and high 
inhibitor concentrations, due to spectrophotometer limitations discussed previously.   
              
 
Figure 31.  Dixon plots for Ct-SI hydrolysis of PNP-glucose in the presence of DAB-1; a) 
partial mixed model, and b) full competitive model. 
 
A secondary plot of Km
app/Vmax
app was constructed to assist in the determination of 
whether introduction of a partiality factor into the inhibition model was justified.  Points on this 
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plot were explained well by a linear model (R2 = 0.964), indicating a lack of evidence for 
hyperbolic inhibition.  The full competitive model was therefore considered the most appropriate 
model to explain the data. 
 
Figure 32.  Replot of Kmapp / Vmaxapp as a function of [DAB-1] for DAB-1 inhibition of PNP-
glucose hydrolysis by Ct-SI. 
 
 
3.9 Inhibition of Nt-MGAM activities by DAB-1 
 
3.9.1 Inhibition of Nt-MGAM maltose hydrolysis by DAB-1 
 
Assuming a full mixed inhibition model (R2 = 0.976), the Ki value for DAB-1 inhibition 
of Nt-MGAM was determined to be 1.82 +/- 0.171 µM.  The α value was 8.75 +/- 2.06.  A full 
competitive model was a much poorer fit to the data (R2 = 0.943).  Mixed inhibition by DAB-1 
would contrast the competitive inhibition of this subunit that was seen with LAB-1.   
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Figure 33.  Michaelis-Menten and Lineweaver-Burk plots for Nt-MGAM hydrolysis of 
maltose in the presence of DAB-1, assuming a full mixed inhibition model. 
 
The Michaelis-Menten plot depicted in Figure 33 recalls the same poor fit for 60 mM 
maltose data points that was seen in the assay with Ct-SI, where a full mixed model was also 
selected as the best model for these data by the global analysis.  The conclusion regarding 
whether the inhibition is truly mixed or competitive should therefore be regarded with some 
uncertainty. 
 
3.9.2 Inhibition of Nt-MGAM PNP-glucose hydrolysis by DAB-1 
 
PNP-glucose hydrolysis by Nt-MGAM was competitively inhibited by DAB-1, with an 
inhibition constant of 3.43 +/- 0.120 µM.  The full competitive inhibition model had a coefficient 
of determination of 0.993, ranking below both partial mixed and partial competitive models.  The 
disparity in R2 values for the three models was very small, and the Dixon plot does not 
overwhelmingly favour a partial inhibition model.  For these reasons, the full competitive model 
was deemed best.  The Michaelis-Menten and Dixon plots are depicted in Figure 34.  
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Figure 34.  Michaelis-Menten and Dixon plots for Nt-MGAM hydrolysis of PNP-glucose in 
the presence of DAB-1, assuming a full competitive inhibition model. 
. 
Once again, PNP-glucose solubility imposed limitations on Vmax estimates that could be 
extracted from this dataset.  This presents a source of error and limits the amount of mechanistic 
information that can be extracted from the dataset. 
3.10 Inhibition of Ct-MGAM N2 and N20 activities by DAB-1 
 
3.10.1 Inhibition of Ct-MGAM N2 and N20 maltose hydrolysis by DAB-1 
 
Ct-MGAM N2 inhibition by DAB-1 was best described by a full mixed inhibition model 
(R2 = 0.959).  Ki and α values were 2.64 +/- 0.353 µM and 6.53 +/- 1.44 respectively.  Michaelis-
Menten and Lineweaver-Burk plots are depicted in Figure 35.  
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Figure 35.  Michaelis-Menten and Lineweaver-Burk plots for Ct-MGAM N2 hydrolysis of 
maltose in the presence of DAB-1, assuming a full mixed inhibition model. 
 
DAB-1 also exhibited mixed inhibition kinetics with Ct-MGAM N20 and maltose (R2 = 
0.984).  The Ki and α values for this inhibition were 2.80 +/- 0.223 µM and 14.22 +/- 2.78.  The 
parameter α assigned to DAB-1 inhibition of Ct-MGAM N20 is more than twice the magnitude 
of that associated with inhibition of Ct-MGAM N2.  Inhibition constants for DAB-1 with both 
enzymes are almost indiscriminable.  Once again it is obvious that the highest substrate 
concentration data points – in this case, 15 mM maltose – fit the mixed model more poorly than 
lower substrate concentration data points. 
3.10.2 Inhibition of Ct-MGAM N2 and N20 PNP-glucose hydrolysis by DAB-1 
 
Inhibition of Ct-MGAM N2 PNP-glucose hydrolysis by DAB-1 was best fit by a full 
mixed model, as was the case with maltose as substrate.  The coefficient of determination for this 
model was 0.991.  Ki and α values were found to be 2.717 +/- 0.183 µM and 8.43 +/- 1.11 
respectively. 
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Figure 36.  Michaelis-Menten and Lineweaver-Burk plots for Ct-MGAM N2 hydrolysis of 
PNP-glucose in the presence of DAB-1, assuming a full mixed inhibition model. 
 
A partial mixed inhibition model was ranked first by R2 (0.993), but the difference 
between this value and that determined for the full mixed model was minute.  This was not 
considered sufficient evidence of partial inhibition.  The Dixon plot is depicted in Figure 37. 
 
 
 
Figure 37.  Dixon plot for Ct-MGAM N2 hydrolysis of PNP-glucose in the presence of 
DAB-1, assuming a full mixed inhibition model. 
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DAB-1 inhibition of PNP-glucose hydrolysis by Ct-MGAM N20 was found to have a Ki 
value of 5.22 +/- 0.531, assuming full competitive inhibition.  There are a number of problems 
with this model: firstly, 30 mM PNP-glucose data points are not well accounted for, and 
secondly, the spread of data points at each substrate concentration is poorly explained.  The R2 
value was only 0.961.  By observing the Michaelis-Menten plot, one can see that 30 mM PNP-
glucose data points are likely higher than they should be, possibly due to experimental error in 
the execution of the assay.  If all 30 mM PNP-glucose data points are associated with 
erroneously high rates, then the competitive inhibition model is most likely not accurate. 
 
Figure 38.  Michaelis-Menten plot for Ct-MGAM N20 hydrolysis of PNP-glucose in the 
presence of DAB-1, assuming a full competitive inhibition model. 
 
The possibility of mixed inhibition in this case was explored further.  Local kinetic 
parameters for individual curves were estimated by nonlinear regression.  The Lineweaver-Burk 
plot from this analysis indicated mixed inhibition.  Calculating inhibition parameters by this 
method, the Ki was found to be 4.82 +/- 0.0317 µM and the α value was found to be 8.55 +/- 
0.693.  Because the global and local methods of analysis indicated two different modes of 
inhibition, the matter was settled qualitatively.  The competitive model from the global analysis 
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was an inexplicably poor fit for 30 mM PNP-glucose data points, while the analysis of individual 
curves did not predict the same poor fit at only one PNP-glucose concentration value.  The 
mixed model is therefore considered a better qualitative explanation for the data seen here. 
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Chapter 4 Conclusions 
 
The higher inhibitory potency of LAB-1, compared to DAB-1, has been well-established 
for rat intestinal α-D-glucosidases in general (Asano et al., 2005).  This trend was also observed 
in kinetic data from the present experiments.  To attempt to account for the difference, it could 
be that one or both of the inhibitors may bind at more than one site on the enzymes, or that LAB-
1 stereochemistry allows for additional interactions that DAB-1 does not have when it binds.  
While the former hypothesis is favoured by some (Asano et al., 2005), there is as yet no concrete 
evidence for an alternate binding site for either LAB-1 or DAB-1 on the mammalian α-
glucosidases studied here. 
Here we have seen that Nt-SI hydrolysis of the disaccharide substrates maltose and PNP-
glucose is more powerfully affected by LAB-1 than it is by DAB-1.  If the two inhibitors do 
happen to bind at the same site, then the stereochemistry of pyrrolidine ring hydroxyl groups 
must somehow contribute to this difference in potency.  Observing the Nt-SI crystal structure, 
solved in complex with the thiosugar sulfonium sulfate inhibitor kotalanol (Sim et al., 2010), I 
hypothesize that LAB-1 and DAB-1 both bind to the -1 subsite of the active site of Nt-SI, where 
the five-member ring of kotalanol is known to bind.  I also hypothesize that this is the general 
way in which these iminosugars inhibit the activities of all five enzymes studied here. 
The -1 subsites of Nt-SI and Nt-MGAM are highly structurally conserved, with very few 
stark differences (Sim et al., 2010).  Their +1 subsites exhibit more structural variability, and this 
is thought to account for the observed differences in substrate specificity (Sim et al., 2010).     
The main -1 subsite difference between the two N-terminal human α-glucosidases is that the 
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residue Trp 327 in Nt-SI is analogous to Nt-MGAM’s Tyr 299.  This residue may play a role in 
favouring LAB-1 binding.  A number of aspartic acid residues in the -1 subsite of Nt-SI, 
including Asp 472, Asp 355, and Asp 571, could form hydrogen bonds with LAB-1 hydroxyl 
groups.  The orientation of hydroxyl groups would largely determine the strength of interactions 
with these residues in the -1 subsite, and this seems to be the most plausible explanation for the 
disparity in LAB-1 and DAB-1 potencies.  Since it is likely that the heteroatom extension of 
kotalanol influences the orientation of its five-membered ring in the Nt-SI and Nt-MGAM active 
sites, the suggestion that DAB-1, with the same ring stereochemistry as kotalanol, binds in 
precisely the same way, is highly speculative.  One molecular docking study has shown that 
LAB-1 derivatives do very likely bind in the enzyme’s active site in the manner discussed here 
(Kato et al., 2015).  They showed that hydrogen bonding with inhibitor hydroxyl groups and 
certain CH-π interactions are essential determinants of the predicted binding capacities of LAB-1 
derivatives (Kato et al., 2015). 
Mixed inhibition of Nt-SI activities by both LAB-1 and DAB-1 could be caused by direct 
interactions with residues Asp 571, the acid/base catalyst, and Asp 472, the catalytic nucleophile 
(Sim et al., 2010).  Since these residues are proximal to the -1 subsite, they could interact 
directly with any of the hydroxyl groups of LAB-1 and DAB-1.  Mixed inhibition kinetics dictate 
that a substrate and an inhibitor can bind simultaneously to an enzyme, so lacking evidence for 
an alternate binding site, the preferred hypothesis is that each of the inhibitors is able to bind to 
Nt-SI in complex with maltose and PNP-glucose substrates.  The resultant complex (ESI) is most 
likely catalytically inactive, based on the preferred full inhibition model.  This leads one to 
believe that one or more catalytic residues is hindered by the binding of these inhibitors.  The 
proposed scheme, wherein LAB-1 and DAB-1 bind to the -1 subsite of the Nt-SI active site, 
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seems congruent with this finding.  If this is the case, LAB-1 and DAB-1 must bind in such a 
way that they do not completely obstruct binding of the substrate.  The fact that thiosugar 
sulfonium sulfate inhibitors including salacinol and kotalanol have been characterized as 
competitive inhibitors suggests that the heteroatom extension plays a very important role in 
blocking the substrate.  LAB-1 and DAB-1 lack the heteroatom extension, and they do not 
exhibit exclusively competitive inhibition kinetics with Nt-SI. 
Full mixed inhibition kinetics were observed with most enzyme-substrate pairs tested 
here, but in some cases, the inhibition was best explained by a full competitive model.  
Considering the possibility that LAB-1 and DAB-1 bind to the -1 subsite of each enzyme’s 
active site, structural differences in the -1 subsite could contribute to these observations.  A few 
convincing cases of competitive inhibition were observed with Nt-MGAM and with Ct-SI.  This 
mode of inhibition could be related to the shape of the +1 subsites of these enzymes; it has been 
hypothesized that the narrowness of the Nt-SI +1 subsite is integral to the binding of α-1,6-linked 
substrates (Sim et al., 2010; Kato et al., 2015).  Perhaps Nt-MGAM and Ct-SI +1 subsites do not 
exercise sufficient constraints on the substrate to allow it to bind simultaneously with LAB-1 or 
DAB-1. 
Ct-MGAM N2 and Ct-MGAM N20 were inhibited by both LAB-1 and DAB-1, and the 
former inhibitor was found to be more potent than the latter by an order of magnitude.  Mixed 
inhibition was observed with both compounds.  The Ct-MGAM isoform N2 structure (Ren et al., 
2011) offers some structural insights that may help explain this mode of inhibition. Firstly, if 
these inhibitors bind to the -1 subsite, there are more aspartic acid residues (five) possibly 
available for hydrogen bonding contacts in Ct-MGAM N2 than there are in -1 subsites of either 
77 
 
Nt-SI or Nt-MGAM (three).  Either the acid/base catalyst or catalytic nucleophile could be 
hindered directly by the binding of LAB-1 and DAB-1, in this scenario. 
Finally, the complete substrate inhibition observed for both Nt-SI and Nt-MGAM at high 
millimolar concentrations of palatinose may be a phenomenon of biological significance if the 
result is also applicable to the hydrolysis of isomaltose.  Palatinose is only consumed in small 
quantities – mainly in honey (Oizumi et al., 2007) – so the phenomenon seen here does not likely 
have very much direct significance.  It is certainly more likely to be an artifact of the 
experimental conditions.  Still, if the same substrate inhibition is observed for isomaltose, it 
could indicate that the phenomenon plays a role in moderating glucose release by slowing the 
hydrolysis of α-1,6-linked starch branch points.  A similar phenomenon has been observed with 
maltase glucoamylase and maltooligosaccharides with up to five units of glucose per substrate 
molecule (Quezada-Calvillo et al., 2007; Quezada-Calvillo et al., 2008).   
Ultimately, the work reported here confirms that LAB-1 is a more potent inhibitor of all 
intestinal α-glucosidases tested than is DAB-1.  LAB-1 exhibits its most potent inhibitory 
activity against Nt-SI, and inhibits all other catalytic subunits to a similar extent.  Considering 
the existing Nt-SI, Nt-MGAM, and Ct-MGAM N2 crystal structures, it appears that the mixed 
inhibition kinetics observed with both inhibitors might be attributable to direct hydrogen bonding 
interactions with catalytic residues proximal to the -1 subsite in each subunit’s active site.   
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Chapter 5 Future Directions 
 
Numerous inhibitory compounds have already been designed on the basis of LAB-1 and 
DAB-1 structures (Kato et al., 2015; Carreiro et al., 2014).  Hydrophobic carbon chains and 
benzyl groups have been added to the pyrrolidine rings in separate ventures to explore the effects 
of particular alterations (Kato et al., 2015; Carreiro et al., 2014).  One possibility that has not 
been tested, to my knowledge, is the introduction of a sulfur atom as the heteroatom in the 
pyrrolidine ring of an otherwise LAB-like compound.  This could help determine the 
significance of the type of heteroatom, and in the absence of a crystal structure in complex with 
this inhibitor, it could perhaps also provide more insights as to how the inhibitor binds.   
Since pyrrolidine iminosugars have proven to be effective inhibitors of many different 
glycoside hydrolases, the question of binding promiscuity in vivo remains an important one 
(Asano et al., 2005).  Because of the impressive potency of LAB-1 as an α-glucosidase inhibitor, 
it would be worthwhile to better characterize the interactions that this inhibitor has with different 
human enzymes.  Salacinol and analogues have been shown to inhibit a Drosophila homolog of 
human Golgi α-mannosidase II (Kuntz et al., 2005) and whether iminosugar inhibitors LAB-1 
and DAB-1 have similar effects remains to be seen.   
Crystallization and structure determination for Ct-MGAM N20 and Ct-SI would prove 
very useful, as well, in developing an understanding of the inhibitory mechanisms and 
differences in potency associated with LAB-1 and DAB-1.  Crystal complexes with human 
intestinal α-glucosidases and either LAB-1 or DAB-1 could also provide a wealth of information 
about how and where the inhibitors really bind. 
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It still seems curious that LAB-1 and DAB-1 can exhibit mixed inhibition, while 
salacinol and its analogues are exclusively competitive inhibitors (Rossi et al., 2006; Sim, 2010; 
Sim et al., 2010; Jones et al., 2011).  While salacinol and derivatives have DAB-1ike hydroxyl 
group orientation about the five-member ring, they also each possess a large heteroatom 
extension.  I have put forward the possibility that the heteroatom extension is crucial to the pure 
competitive nature of the inhibition by salacinol and its derivatives.  It would be interesting to 
see if creating and testing salacinol analogues with heteroatom extensions of varying length 
might indicate the point at which the inhibitor’s heteroatom extension becomes so large that it 
obstructs binding of the substrate altogether. 
Finally, whether or not there is any benefit to purposefully designing mixed inhibitors of 
mammalian small intestinal α-glucosidases is worthy of some consideration.  Most α-glucosidase 
inhibitors used in the management of type two diabetes are purely competitive.  Effectively it 
seems there is really no benefit to one type of inhibition over the other; the most important goal 
is to selectively inhibit particular catalytic subunits with different compounds.  In any case, it is 
my hope that the findings reported here will one day be of aid in the development of more highly 
selective and effective α-glucosidase inhibitors. 
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Appendix I 
 
Documentation of a Ct-MGAM N2 nickel column purification, performed as described in 
the Materials and Methods, is included in Figures 39, 40, and 41. 
 
Figure 39.  Ct-MGAM N2 purification: Expression media, flow through, and 10 mM 
imidazole elutions (14% denaturing gel). 
 
Numbered gel columns indicate both the concentration of imidazole used to elute the 
proteins in each sample and the order of elutions (ex. 10-1 is the first elution of a series using a 
buffer with 10 mM imidazole). 
Figure 40 contains a photo of another reducing gel showing elutions from this 
purification. 
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Figure 40.  Ct-MGAM N2 purification: 75 – 250 mM imidazole elutions (14% denaturing gel). 
 
Final purified proteins from the Ct-MGAM N2 purification are shown in Figure 41.  Ct-
MGAM N2 from the first column (75-250: Ct-MGAM N2) was used in assay for inhibition of 
PNP-glucose hydrolysis by DAB-1. 
                                                        
Figure 41.  Ct-MGAM N2 purification: final preparations after protein concentration 
(10% denaturing gel). 
